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Abstract  
Mycobacterium tuberculosis (Mtb) causes human tuberculosis, and more 
people die of it than of any other pathogen in the world. Immunodominant antigens 
elicit the large majority of T cells during an infection, making them logical vaccine 
candidates. Yet, it is still unknown whether these immunodominant antigen-
specific T cells recognize Mtb-infected cells. Two immunodominant antigens, 
TB10.4 and Ag85b, have been incorporated into vaccine strategies. Surprisingly, 
mice vaccinated with TB10.4 generate TB10.4-specific memory CD8+ T cells but 
do not lead to additional protection compared to unvaccinated mice during TB. 
Ag85b-specific CD4+ T cells are also generated during vaccination, but the 
literature on whether these cells recognize Mtb-infected cells is also inconsistent.  
We demonstrate that TB10.4-specific CD8+ T cells do not recognize Mtb-
infected cells. However, under the same conditions, Ag85b-specific CD4+ T cells 
recognize Mtb-infected macrophages and inhibit bacterial growth. In contrast, 
polyclonal CD4+ and CD8+ T cells from the lungs of infected mice can specifically 
recognize Mtb-infected macrophages, suggesting macrophages present antigens 
other than the immunodominant TB10.4. The antigen location may also be critical 
for presentation to CD8+ T cells, and live Mtb may inhibit antigen presentation of 
TB10.4. Finally, we propose that TB10.4 is a decoy antigen as it elicits a robust 
CD8+ T cell response that poorly recognizes Mtb-infected macrophages, allowing 
Mtb to evade host immunity.  
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CHAPTER I. INTRODUCTION 
A well-documented past 
  Mycobacterium tuberculosis (Mtb) causes human tuberculosis (TB), killing 
more people than any other infection in the world [1]. Robert Koch first isolated 
and identified the disease-causing bacterium in 1882, though the human struggle 
against TB can be found speckled throughout history, beginning as early as 8000 
BCE [2]. Of note, Homer, in Odyssey, described it as a “grievous consumption 
which took the soul from the body” in 800 BCE [2]. Hippocrates called a disease 
with similar symptoms “phthisis,” Greek for “to waste away,” in 400 BCE [2]. From 
the 14th to the 19th century, it took on the names of the “King’s evil,” “consumption,” 
and “the great white plague” [2]. Yet, despite its long and storied existence, we 
have yet to eradicate it.  
1.7 billion people in the world is infected with Mtb [3]. Most of the new cases 
occur in South-East Asia and Africa, and the total global count is 10.4 million new 
cases per year [1]. Of those new cases, about 20% are due to malnourishment, 
10% due to HIV co-infection, and 1% due to diabetes. From 2000 to 2016, the 
mortality rate of TB has declined by 37%; nonetheless, the current mortality rate 
translates to 1.6 million people dying each year [1]. The mortality rate is higher 
among those co-infected with HIV or those with diabetes. The WHO estimates the 
global economic burden due to tuberculosis to be $12 billion annually. Since the 
large majority of tuberculosis endemic regions are in developing nations, this 
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disease burden poses a significant threat to the future development of those 
countries [1].  
Given the huge disease burden, antibiotics and vaccines are logical choices 
in curtailing the spread of TB. The only clinically approved vaccine, Bacillus 
Calmette-Guerin (BCG) vaccine, is derived from an attenuated strain of 
Mycobacterium bovis, which causes tuberculosis in cattle. It has been used since 
1921, and many endemic countries have compulsory vaccination [1]. However, 
while earlier studies of the BCG vaccination show risk reduction of contracting TB 
as much as 50% [4], later studies demonstrate that the protection can be variable 
in adults [5]. Depending on the geographical location and in vitro culturing 
conditions of the BCG, a large heterogeneity, ranging from 0% to 80%, in its 
protectiveness exists [5]. Nonetheless, the protection is more consistent in 
children, when given at infancy and for preventing tuberculosis-induced meningitis 
[6, 7]. For patients with TB, antibiotic treatment requires a cocktail of drugs taken 
over a long period of time. In 1952, the first combination therapy including 
streptomycin, aminosalicylic acid and isoniazid was used in a 2-year treatment 
course [8]. Today, we not only have first-line treatment, but also, due to rising multi-
drug-resistant (MDR) and extensively-drug-resistant (XDR) Mtb, second-line 
treatment with an urgent need for new antibiotics against future drug resistance 
[8]. Despite large public health efforts and directly-observed-treatment (DOTS) 
programs, lack of compliance, or non-adherence, to medication regimen remains 
a challenge and adds to the complexity of curing TB patients [9].  
12 
 
These facts may present a discouraging view on our likelihood of 
eradicating TB. However, it is not due to a lack of trying that we do not have a 
short, effective treatment or a consistently protective vaccine. Antibiotic and 
vaccine development remain high priorities in the research community, with 17 TB 
drugs and 12 TB vaccines in various stages of clinical trial and development [1, 8, 
10]. Instead, one may infer that the long history shared by humans and Mtb has 
resulted in a bacterium that is extremely well adapted to survive and thrive within 
its host. Genetic analysis of 259 strains of Mtb point to a co-evolution process for 
over 70,000 years [11]. There is also hyperconservation of epitopes recognized by 
human T cells across different Mtb strains in the world, leading to the theory that 
Mtb has evolved to allow certain immune responses to occur that may benefit its 
survival [12, 13]. Not surprisingly, Mtb clinical isolates that have faster mutation 
rates lead to higher likelihood of being multi-drug-resistant in infected patients [14]. 
These studies reflect the extent of which Mtb has co-evolved with humans. They 
also highlight the importance and necessity of understanding how Mtb interacts 
with the host, especially host immunity, if we want to discover new therapies and 
vaccines. 
 
A cough and a life-long partner  
Mtb is an acid-fast, rod-shaped, aerobic, intracellular facultative bacterium. 
Its thick, “waxy,” mycolic acid cell wall makes it tough for antibiotics to penetrate 
through [15]. Indeed, a key difference between the virulent laboratory strain of Mtb, 
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H37Rv, and its attenuated, non-virulent derivative, H37Ra, is a mutation in hadC, 
which plays a role in the synthesis of mycolic acid [16]. Mtb is a slow growing 
microorganism, having a doubling time of roughly 24 hours in vitro [17, 18]. In vivo 
doubling time of Mtb is complex, given that Mtb responds and changes its growth 
rates in the presence of host immunity. In high dose aerosol infections (i.e. ~200 
colony forming units (CFU) initial dose) of C57BL/6 mice, the in vivo growth rate 
shows a doubling time of 24.6 hours during the first 2 weeks of infection and 1,676 
hours during week 4 through 16 post-infection [19]. The slow doubling time may 
allow Mtb to reduce the expression of its proteins in order to evade host immunity. 
TB pathogenesis is just as complex as Mtb itself. Mtb is transmitted via 
aerosolized droplets containing the bacterium from an infected person’s cough. 
Once in the airway, the droplets travel down into the distal parts of the lung.  Here, 
inside the alveolar spaces, phagocytic cells such as alveolar macrophages and 
dendritic cells will engulf the free Mtb, just as it would for any other foreign 
pathogen [20]. Rather than being eliminated by the macrophages’ innate 
antimicrobial mechanisms, however, Mtb survives and replicates within the 
macrophages [21, 22]. Over time, recruitment of other immune cells leads to the 
containment of infection, often via the formation of granulomas [23]. Of all people 
infected with TB, 90-95% of the patients will contain the infection and live without 
any symptoms, or asymptomatically [22]. These patients have “latent TB” and do 
not transmit the disease. However, the other 5-10% of the patients, often those 
who are immunocompromised, will develop symptoms, such as fever, coughing 
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with sputum production, coughing up blood (or hemoptysis), weight loss, and night 
sweats. These patients have “active disease” and will transmit TB to others via 
coughing. Though it is a primarily pulmonary infection, TB can disseminate to and 
cause disease in other areas of the body, including scrofula in the cervical lymph 
node, meningitis, Pott’s disease in the spine, cutaneous tuberculosis such as lupus 
vulgaris, and disseminating to the gastrointestinal and genitourinary tracts [24-26]. 
Of the 90-95% of patients who have latent tuberculosis, there is also a 10% chance 
of them progressing to active disease. Immunocompromised patients, such as 
those with HIV/AIDS or uncontrolled diabetes, are much more likely to develop 
active disease than their immunocompetent, latently infected counterparts [27, 28]. 
The pathogenesis of TB indicates 2 important observations: 1) Mtb can live a 
dormant lifestyle in order to persist within the host, and 2) our immune responses 
are sufficient to contain, though not sterilize, the infection. 
 
Innate immune response to Mycobacterium tuberculosis  
Both the innate and adaptive immune responses help the host contain Mtb. 
The importance of innate immune response has been shown by observing a 
difference in the bacterial burden between susceptible and resistant rabbits as 
early as 7 days post infection, before the initiation of adaptive immunity [29]. BCG 
vaccination has effectively prevented disseminated disease, such as meningitis, in 
children but not primary disease [6, 7], supporting the argument that the adaptive 
immune response does not prevent initial infection [29]. While most Mtb-infected 
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people either contain the infection or have active disease, there is a third 
population who presumably can clear the infection [23]. The best evidence of this 
population comes from studying household contacts in endemic regions. In 
households where there was at least one case of TB, epidemiologists followed 
others living in the same households and recorded the status of their tuberculin 
skin test (TST) [30]. The TST is based on a type IV hypersensitivity reaction, and 
a positive TST means that individual has a memory T cell response to the 
tuberculin antigen, indicating prior exposure or infection. Over the 2 years of follow 
up, while some converted their TST from negative to positive, others, named 
“persistent TST negatives,” never converted [30]. While there has been 
controversy over the specificity of the test [31], this data supports the notion that 
innate immune response is responsible for these resisters in clearing the infection.  
Before arriving at the distal airways where the macrophages await, Mtb first 
encounters numerous airway epithelial cells that line the respiratory tract [32]. The 
epithelial cells form a physical barrier to foreign pathogens by having tight junctions 
and adherens junctions, and damage to that barrier leads to more successful 
invasion by Mtb [32-34]. Using human tissues and organ structures to mimic the 
respiratory tract, Middleton et al find that Mtb do not attach to healthy areas of the 
mucosa but preferentially attach to damaged mucosa where the underlying 
extracellular matrix is exposed [34]. Interestingly, the adherence to these surfaces 
decrease significantly when the human tissues are pre-treated with fibronectin 
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attachment protein (FAP) or Ag85b protein, confirming that Mtb uses Ag85b to 
attach to the fibronectin in order to infect cells [34].  
After invading and translocating across the respiratory tract epithelium [35], 
Mtb can be phagocytosed by resident alveolar macrophages, dendritic cells, and 
monocyte-derived macrophages via complement receptors (for opsonized 
bacteria) and via mannose and scavenger receptors (for nonopsonized bacteria) 
[36]. Macrophage recognition of Mtb occurs via Toll-like receptors (TLR) such as 
TLR2 as well as TLR9 and also via C-type lectin receptor [22, 37]. The result is the 
production of pro-inflammatory cytokines, including TNFα, IL-1B, IL-6, IL-12, IL-15 
and IL-18, as well as anti-inflammatory cytokines, including IL-10, TGFB, and IL-4 
[38, 39]. Of note, tumor necrosis factor (TNF) is important in human TB patients 
because latently infected patients have an increased risk of developing active TB 
after using anti-TNF treatments, often prescribed to manage symptoms of Crohn’s 
disease and rheumatoid arthritis [40]. Together, these cytokines can activate 
macrophages and also help differentiate T cells, though a disruption in the fine 
balance between the pro- and anti-inflammatory cytokines can lead to detrimental 
effects on the host [41].  
Macrophages kill Mtb with a variety of mechanisms. IFNγ production by T 
cells can activate infected macrophages to kill Mtb, using a process dependent on 
vitamin D [42]. Two important mechanisms for macrophage killing are the 
production of reactive oxygen intermediates (ROI) and reactive nitrogen 
intermediates (RNI) [43]. Activated macrophages can undergo apoptosis to kill 
17 
 
Mtb, and the process depends on both caspase and nitric oxide (NO) [44]. Whether 
cells die of apoptosis or necrosis also has consequences. Apoptotic vesicles that 
bleb off from the dying macrophage may contain live Mtb, and these vesicles are 
eliminated by uninfected macrophages that engulf them [45]. This mechanism, 
termed efferocytosis, allows the uninfected macrophage to phagocytose the dying 
cells and form a phagosome around the previous phagosome that contain the live 
Mtb. This double phagosome, or efferosome, allows for the efficient recruitment 
and fusion of lysosomes and subsequent elimination of the Mtb within [46]. 
Furthermore, mice with a more susceptible allele in the sst1 (supersusceptibility to 
tuberculosis 1) locus led to increased necrosis of infected macrophages and higher 
bacterial burden compared to mice with a more resistant allele that led to more 
apoptosis of infected macrophages and lower bacterial burden [47] [48].  
Neutrophils and natural killer (NK) cells are also important innate immune 
cells during TB. Neutrophils are recruited to the lung after infection [49]. In patients 
with active TB, neutrophils outnumber macrophages in both sputum and 
bronchoalveolar lavage (BAL) fluid, and they also contain more Mtb than 
macrophages and epithelial cells [50]. The role of neutrophils during infection 
remains incompletely understood. There is both evidence that shows neutrophils 
as protective [51] and as harmful to the host [52] [32]. Neutrophil influx may 
correlate with increased severity of disease and inflammation [49]. Regulation of 
neutrophil recruitment, through the inhibition of CD4+ T cells’ production of IL-17, 
is necessary to prevent pathogenic neutrophil accumulation and detrimental 
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inflammation in the lung [53]. Natural killer (NK) cells also contribute host defense. 
During co-culture with Mtb-infected monocytes, NK cells have been shown to 
upregulate activating receptors NKp46 and NKG2D, both of which are required for 
successful lysis of Mtb-infected monocytes [54]. Interestingly, invariant NK (iNK) T 
cells, which do not form memory cells, can be rapidly activated by IL-12 and IL-18, 
cytokines produced by macrophages. They secrete granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which is critical for the suppression of Mtb 
growth in infected cells [55].  
Ultimately, the innate immune response does not clear the infection, but it 
does initiate the formation of granulomas to contain the infection [56]. Granulomas 
are collections of foamy macrophages and multinucleated giant cells, and, in the 
context of TB, these cells often contain live bacteria [57]. In the zebra fish model, 
which lacks an adaptive immune response, granulomas form after infection with 
Mycobacterium marinum, supporting that notion that innate immunity initiates 
granuloma formation [58]. The maintenance of the granuloma and subsequent 
control of the infection, however, requires the adaptive immune response [23]. 
 
Adaptive immune response to Mtb 
The adaptive immune response is required for the successful containment 
of Mtb [41, 59, 60]. T cell priming during TB requires dendritic cells (DCs) [61] and 
occurs in the mediastinal lymph node [62]. However, a unique characteristic of the 
adaptive immune response during TB is its delay in onset. In acute infections such 
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as influenza or LCMV, the initiation of adaptive immunity occurs within 3 to 5 days 
post infection. Yet the adaptive immune response to TB is not detected until 42 
days post exposure in humans [63]. In mice, the initiation of antigen-specific T cell 
responses does not occur until day 11 post aerosol infection and depends more 
on the bacterial burden in the lymph node where priming occurs rather than the 
lung where the infection is [64]. In both Mtb-infected C57BL/6 and C3H mice, Mtb 
must disseminate to the lymph node prior to T cell priming, though the 
dissemination and T cell responses occur faster in the more resistant C57BL/6 
mice [65]. Interestingly, Griffiths et al have shown that delivering DCs primed with 
Mtb antigens to vaccinated mice at the time of aerosol infection bypasses this 
“bottleneck” and accelerates the initiation of the T cell responses [66]. This data 
also argues that Mtb antigen load during early stages of infection may not be 
sufficient to initiate prompt T cell priming. 
Despite the delay, once T cell immunity is initiated, CD4+ and CD8+ T cells 
play a crucial role in controlling the bacterium. Monoclonal antibody depletion of T 
cells in thymectomized, Mtb-infected mice leads to higher bacterial burden and 
shorter survival time compared to control mice [67, 68]. Adoptive transfer of T cells 
into sub-lethally irradiated, Mtb-infected mice leads to significant protection, and it 
is the splenic T cells that are responsible for this protection [69]. Mtb-infected, 
TCRαβ-/- mice, which lack αβ T cells, has 2-log higher bacterial burden and live 
210 days shorter than the Mtb-infected, wild type mice [70]. These data show that, 
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after T cells appear in the lungs of infected mice, the bacterial burden can be 
controlled throughout infection [60].  
 
The role of CD4+ T cells 
Th1 CD4+ T cells have long been thought of as the most important part of 
the adaptive immune response, based on their ability to produce IFNγ, TNF and 
IL-2 during infection [23]. T cells from pleural effusion exudate of TB patients 
produce high amounts of IFNγ when co-cultured with purified protein derivative 
(PPD), which is made from sterilized Mtb cultures, and this response diminishes 
when antibodies against CD4+, but not CD8+, T cells are added [71]. As described 
to above, IFNγ is important in activating macrophages to kill intracellular bacteria. 
In Mtb-infected IFNγ-/- mice, there is a much higher bacterial burden in the lung, 
spleen, and liver as well as worsened pathology [72]. These mice also succumb to 
Mtb much earlier compared to WT mice, around 50 days post aerosol infection vs. 
over 300 days [70]. Patients with Mendelian susceptibility to mycobacterial 
diseases (MSMD), who may have mutations in the IFNGR1 or IFNGR2 genes that 
normally encode part of the IFNγ receptors, show increased susceptibility to 
mycobacterial diseases [73, 74]. Several studies have demonstrated that CD4+ T 
cells are an importance source of IFNγ during infection [75-77]. However, there is 
controversy as to how protective IFNγ is during infection. CD4+ T cells isolated 
from Mtb-infected mice suppress Mtb growth in Mtb-infected, IFNγR-/- 
macrophages, indicating that IFNγ may be dispensable [78]. More recently, 
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adoptive transfer of either WT or IFNγ-/- CD4+ T cells into Mtb-infected, RAG1-/- 
mice demonstrated that the IFNγ secreted by the WT CD4+ T cells contributed only 
30% of the total bacterial burden reduction by the CD4+ T cells [79]. Increasing the 
production of IFNγ from CD4+ T cells actually accelerated the demise of the 
infected mice, suggesting that there is a balance of IFNγ production in order to 
achieve optimal control [79]. Interestingly, the importance of TNF has also come 
under question after discovering that TNF-/- CD4+ T cells can afford protection at a 
similar level as WT CD4+ T cells [79]. A subtlety in these studies is that the 
contribution of CD4+ T cells is more important during early stages of the infection, 
and other immune cells play an important role in sustaining control throughout later 
stages of infection [80]. While these studies suggest an incomplete understanding 
of the contribution made by Th1-CD4+ T cell cytokines during infection, it is well 
appreciated that CD4+ T cells are required for optimal protection against Mtb [77]. 
In humans, CD4+ T cells are indispensable, as evidenced by the increased risk of 
getting active TB disease in a co-infected HIV patient whose CD4+ T cells have 
decreased significantly [81].   
Other subsets of CD4+ T cells also play a role during Mtb infection. Th2 
CD4+ T cells, which produce IL-4 and IL-10, arise during TB. However, studies 
suggest that they may not be beneficial to the host. Th2 responses may be induced 
by Mtb virulence factors in order to dampen the Th1 response in favor of Mtb 
survival [82]. In mice, antibody blockade of IL-10R during BCG vaccination 
increased protection against subsequent Mtb infection and led to increased Th1 
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and Th17 responses [83]. In patients with active disease, cytokines made by Th2 
cells can be detected, and this has been associated with active, progressive 
disease [84, 85]. Another subset of CD4+ T cells made during TB is Th17 cells. 
They produce IL-17, which is important in recruiting neutrophils to the lung 
environment and may contribute to protective immunity to Mtb [86, 87]. IL-17+CD4+ 
T cells have been identified from peripheral blood mononuclear cells (PBMCs) of 
TB patients, with the frequency being higher in patients with latent disease, leading 
to the idea that IL-17 producers may help control Mtb [88]. T regulatory (Treg) cells 
proliferate and accumulate at the site of infection, but they have been implicated 
in the delay of CD4+ and CD8+ T cell priming [89]. Interestingly, depletion of Tregs 
before aerosol infection led to suppression of bacterial growth in infected mice, 
supporting the idea that Tregs do not promote a protective response [90]. 
 
The role of CD8+ T cells 
The requirement of CD8+ T cells for optimal control of Mtb has only recently 
been fully appreciated. Early studies involving adoptive transfer of splenic immune 
cells to Mtb-infected mice showed reduced bacterial burden in sub-lethally 
irradiated mice, and antibody depletion confirms that the Ly-2+ (i.e., CD8+) T cells 
are responsible for the reduction [91]. A classic study shows that infection of mice 
deficient in β2-microglobulin (β2m), a key component of the MHC class I molecule, 
results in greater bacterial burden, shorter survival, and more necrotic granulomas, 
all signs of uncontrolled disease, when compared to WT mice [92]. However, β2m-
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/- mice also results in an iron-rich environment that promotes Mtb growth, 
suggesting that the β2m-/- susceptibility phenotype may be due to bacterial growth 
in a nutrient rich environment rather than a lack of effective MHC class I 
presentation [93]. Nonetheless, other studies examining the MHC class I pathway 
have shown the importance of CD8+ T cells during TB. Double knockout of H-2Kb 
and H-2Db in mice increased their susceptibility to Mtb, both through the IV and 
aerosol infection route [94]. In another classic study, IV infection of TAP-/- 
(transporter associated with antigen presentation) mice, which lack of MHC class 
I presentation, succumbed to Mtb much earlier than their wild type counterparts 
[95].  
The role that CD8+ T cells play during TB has often been overshadowed by 
the perceived importance of the CD4+ T cells. Using high dose IV infection (~ 5x106 
H37Rv), Leveton et al demonstrate that antibody depletion of CD4+ T cells results 
in disease outcomes similar to the depletion of both CD4+ and CD8+ T cells, while 
depletion of CD8+ T cells alone shows similar survival as a non-depleted mouse 
[67]. Other antibody depletion studies, where depletion of CD4+ T cells leads to 
higher bacterial burden compared to depletion of CD8+ T cells, have confirmed this 
finding as well [68]. Mogues et al show that MHC class II-/- mice died about 160 
days earlier than MHC class I-/- mice [70]. At first glance, these data suggest that 
the contribution by the CD4+ T cells may be more important than that of CD8+ T 
cells. However, the use of antibody depletion and genetic knock out mice only 
allows for studying each cell subset individually and misses the relative 
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contribution of each subset throughout the entire infection. It is well known that 
CD4+ T cell help is required for successful generation of effector and memory CD8+ 
T cells [96-100]. Therefore, depleting CD4+ T cells when assessing the function of 
CD8+ T cells may disrupt the development of fully functional CD8+ T cells. In Mtb-
infected mice without CD4+ T cells, effector CD8+ T cell activation and subsequent 
IFNγ production [101] as well as cytotoxic activity is diminished significantly [102]. 
During infection, IFNγ-/- CD4+ T cells result in a decrease in CD8+ T cell recruitment 
to the lung and also fewer IFNγ- or TNF-producing CD8+ T cells [76]. While data 
suggests that a small primary CD8+ T cell response may occur without CD4+ T cell 
help, CD4+ T cells are definitely required during secondary response [100]. 
Together, these data suggest that assessing the effect of CD8+ T cells by depleting 
CD4+ T cells may inadvertently harm the development of CD8+ T cells, thus giving 
the illusion that CD8+ T cells make relatively small contribution to the overall 
immunity against Mtb. 
Recent studies have confirmed the importance of CD8+ T cells during TB. 
Transfer of antigen-specific CD8+ T cells cloned from vaccinated mice confer 
protection to Mtb-infected, unvaccinated mice [103].  Memory CD8+ T cells have 
also been shown to be important during TB [104, 105]. Transfer of a CD4+, PPD-
(Purified Protein Derivative)-specific T cell line did not control Mtb in 
thymectomized CBA mice, suggesting that CD8+ T cells are necessary for optimal 
control of Mtb [67]. In the above section, the importance of IFNγ, and especially 
IFNγ from CD4+ T cells, has been described. A study examining CD4+ KO or MHC 
25 
 
class II-/- mice show that IFNγ production in the lungs does not diminish after 
infection, and that IFNγ production comes from CD8+ T cells [106].  In chronic 
infection, CD8+ T cells increase in their frequency of IFNγ producers [107]. By 
using a latent TB model where aerosol-infected mice were first treated with 
antibiotics before allowing the bacterial burden to rise, monoclonal antibody 
depletion of CD8+ T cells during chronic infection led to a significant increase in 
the bacterial burden, whereas depletion of CD4+ T cells did not [108]. In non-
human primate models, depletion of CD8+ T cells diminished the protection against 
Mtb in BCG-vaccinated rhesus macaques [109]. These data show that CD8+ T 
cells are important in animal models of TB, and their contribution may be better 
appreciated during the chronic phase of infection.  
How CD8+ T cells carry out their effector functions during TB is also of great 
importance to the immune response. Cytotoxic CD8+ T cells carry out their effector 
functions by secreting cytokines such as IFNγ and TNF or through T cell receptor 
(TCR) dependent cytolysis, including the delivery of perforin and granzymes as 
well as Fas-FasL interactions [23]. During TB, CD8+ T cells can make both TNF 
and IFNγ [60], which are important for controlling Mtb [70, 110]. Two studies show 
that cytokine production is the main mechanism of protection by CD8+ T cells [111, 
112], however, mounting evidence suggests an equally important role for cytolytic 
mechanisms. CD8+ T cells in the lungs of Mtb-infected or vaccinated mice can lyse 
Mtb-infected macrophages [72, 103, 113, 114]. These CD8+ T cells express 
perforin in vivo [113], and the killing depends on the delivery of cytotoxic 
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granzymes and perforin to the target cells [115-117].  Furthermore, CD95/CD95L 
deficient mice, lacking the Fas-FasL killing mechanism, exhibit greater bacterial 
burden during the chronic phase of infection [118]. In humans, patients with active 
TB often have CD8+ T cells with lowered expression of granzyme B compared to 
patients with latent TB or healthy individuals, hinting at the importance of granzyme 
B in control of TB [119]. Moreover, CD8+ T cells’ delivery of granulysin is an 
important effector function during human TB control [120]. A lack of the granulysin 
homolog in mice has made it challenging to study its functions, but it does not 
exclude the idea that there exists an undiscovered molecule delivered by CD8+ T 
cells that mediate the same effects during murine TB infection [121]. 
The adaptive immune response is essential in controlling TB and 
maintaining latency in chronically infected people and mice. The role of CD8+ T 
cells during TB is complicated, but emerging evidence over the past twenty years 
have reinforced the idea that CD8+ T cells contribute to the optimal control of TB. 
Despite their many abilities, both CD4+ and CD8+ T cells can only contain and not 
eradicate Mtb from the host. This may reflect yet another consequence of the co-
evolution of Mtb and humans. Indeed, a body of evidence exists showing that Mtb 
has evolved to have sophisticated immune evasion mechanisms. 
 
Immune evasion and subversion by Mycobacterium tuberculosis  
Mtb persists in humans because of its highly evolved ability to evade and 
subvert the host immunity [122]. Macrophages engulf Mtb via receptor mediated 
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phagocytosis, but the phagosomes cannot undergo successful acidification once 
the Mtb is inside [123, 124]. Acidification is one of the important mechanisms for 
macrophages to defeat engulfed pathogens [43]. Mtb can survive quite well in a 
slightly acidified environment, around pH 5.0-5.5, however, it does not survive in 
pH < 4.0 [125]. Studies show that vacuole containing Mycobacterium avium and 
phagosomes containing Mycobacterium bovis BCG have a pH of 6.3 to 6.5 [126, 
127]. The Mtb phagosomes appear immature as they display more early-
endosomal markers, and they have limited ability to fuse with lysosomes [123, 
128]. The failure of phagolysosomal fusion is a key mechanism that allows for Mtb 
to survive intracellularly [129]. Mtb subverts vesicular trafficking by interfering with 
SNARE (soluble NSF attachment protein receptor) proteins and Rab family 
proteins, specifically preventing the recruitment of Rab7 [122, 130]. Mtb also 
inhibits innate immunity through its protein PtpA, which binds to ubiquitin in the 
host cells and impairs signaling pathways involved in Jnk, p38 and NF-κB [131]. 
Mtb genes such as noxR1 has been implicated in helping the bacterium become 
resistant to RNI and ROI antimicrobial mechanisms [132].  
Cell death modality plays an important role in defense against Mtb. 
Apoptosis, where the cell undergoes programmed cell death that leaves the cell 
membrane intact, is beneficial to the host during TB [133]. In human macrophages 
infected with Mtb, both TNF and Fas-FasL pathways promotes apoptosis and limits 
Mtb growth, whereas nonapoptotic cell death has no beneficial effects [134]. Mtb 
can disrupt the plasma membrane of the infected cell and prevent prostaglandin 
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E2 (PGE2)-dependent plasma membrane repair by manipulating the macrophage 
to upregulate lipoxin A4 (LXA4) production [135]. Then, the damaged macrophage 
undergoes necrosis rather than apoptosis. Whereas apoptotic cells can be easily 
engulfed by uninfected cells, allowing the clearance of Mtb via efferocytosis, 
necrotic cells lack the receptors that allow for efferocytosis [45, 46]. Necrosis of 
the infected macrophages allows escape of the Mtb to infect other cells, 
propagating the infection [136]. These data show that Mtb subverts macrophage 
defenses to avoid elimination. 
Mtb evades and resists T cell responses as well [137]. Mtb delays the 
initiation and recruitment of T cell immunity to the lung, promoting the 
establishment of a persistent infection [60]. Mtb can subvert the eicosanoid 
pathways to delay priming of T cell immunity. Mtb has been shown to induce the 
production of lipoxin A4 (LXA4), which inhibits prostaglandin E2-dependent plasma 
membrane repair and leads to more necrosis of the infected cell [135]. Infection of 
Alox5-/- mice, which cannot make LXA4, leads to faster generation of antigen 
specific CD8+ T cells during priming and also enhanced CD4+ and CD8+ T cell 
responses, suggesting a mechanism by which Mtb prevents the initiation of T cell 
priming [138]. A proapoptotic mutant of Mtb, the nuoG mutant [139], leads to faster 
appearance of Mtb in the mediastinal lymph node and subsequent earlier priming 
of antigen specific CD4+ T cells, compared to the wild type H37Rv [140]. Studies 
in both mouse models and T cells isolated from TB patients have also shown that 
Mtb infection leads to high IL-10 production from the T cells, which impairs priming 
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and worsens disease outcome [141, 142]. Antibody blockade of IL-10 during BCG 
vaccination enhanced adaptive immune response and decreased bacterial burden 
for both the resistant C57BL/6 and the susceptible CBA/J mice [83]. Infection of 
mice with recombinant ovalbumin (rOVA)-expressing BCG reduced CD8+ T cell 
priming compared to when the mice were infected with rOVA-expressing Listeria 
monocytogenes; but increasing the amount of OVA being expressed corrected the 
defect [143]. Ag85b, an important protein made by Mtb that helps the bacteria 
attach to fibronectin during infection, is transiently expressed during TB [144]. 
Indeed, the lowered expression of Ag85b by 3 weeks post infection has been 
attributed as the reason for a lack of effective response by Ag85b-specific CD4+ T 
cells [144]. Moreover, correcting this phenotype by having a Mtb strain 
constitutively expressing Ag85b led to better CD4+ T cell responses [145]. These 
data show that Mtb turns down its expression of antigens in order to evade 
adaptive immunity. Human monocyte derived DCs, when matured with the early 
secreted antigenic target of 6-kDa (ESAT-6) protein from Mtb, induce a Th17 T cell 
response and inhibited Th1 T cell response [146]. ESAT-6-treated, Mtb-infected 
PBMCs decrease IFNγ production by T cells [147]. The Mtb 19-kDa lipoprotein 
interferes with MHC class II antigen presentation [122]. In humans studies, Mtb 
can infect fibroblast cells and downregulate IFNγ-induced MHC class II expression, 
leading to defective antigen presentation to the CD4+ T cells [148]. In mice, 
inhibition of IFNγ-induced MHC class II expression has also been documented 
[149]. Mtb-infected macrophages produce membrane vesicles containing Mtb 
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byproducts and proteins, and these vesicles can impair the activation and priming 
of naïve CD4+ T cells during infection [150]. Mtb-infected DCs can undergo an 
active, kinesin-2 dependent export of Mtb antigens out of the infected cells, 
allowing the infected cells evade host T cell responses [151].  
The above data show that Mtb has an arsenal of immune evasion and 
subversion mechanisms to thrive within the host. Some of the mechanisms allude 
to Mtb’s ability to evade immune recognition. While Mtb-specific CD4+ and CD8+ T 
cells are generated during infection, whether they can recognize Mtb-infected cells 
remain inconclusive.  
 
Recognition of Mycobacterium tuberculosis-infected cells  
T cell recognition defined 
  In order for CD4+ and CD8+ T cells to carry out their functions, they must 
first be activated, and this activation is often referred to as recognition of cognate 
peptides by the T cells. Professional APCs present both foreign and self-peptides 
on their cell surfaces, and the T cells sample the APCs to see if they may recognize 
their peptides. CD4+ and CD8+ T cells differ in their recognition pathways. MHC 
class I molecules are responsible for presenting to CD8+ T cells, whereas MHC 
class II molecules present to CD4+ T cells [152]. MHC class I presentation focuses 
mainly on proteins generated inside a cell, where the proteins are degraded by the 
proteasome and loaded for presentation [153, 154]. However, MHC class I 
presentation can also involve “cross-presentation,” where antigens of exogenous 
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nature can be taken up by the APC and presented onto MHC class I molecules 
[155, 156]. Cross-presentation, commonly defined using DCs, can occur via the 
cytosolic pathway, where phagocytosed antigens are exported out into the cytosol 
first to be processed by the proteasome before loaded onto MHC class I [157]. 
Cross-presentation can also occur via the vacuolar pathway, where the 
phagocytosed antigen is degraded in the phagosome and loaded directly onto 
MHC class I molecules on the phagosomal membrane [158]. The MHC class II 
pathway mainly presents extracellular antigens phagocytosed by the APCs, 
though they can also present self-proteins degraded in the endosomes [152, 159]. 
T cell recognition requires 1) T cell receptors to interact with the peptide-loaded 
MHC molecules, 2) costimulatory molecule interaction between CD28 (on the T 
cells) and B7 (on the APCs), and, for optimal priming and function, 3) cytokines 
such as IL-12, type I IFNs, and, in the context of TB, IL-27 [60, 160]. 
Differentiating cognate from non-cognate recognition remains problematic 
when assessing recognition. This challenge arises from the observation that T cell 
IFNγ production, a common readout of recognition, can be non-specifically induced 
by IL-12 and IL-18 secreted by infected cells, in both  Mtb and other infections [55, 
161-163]. This means that, rather than TCR-dependent activation or recognition, 
these cytokines can activate T cells independent of TCR interacting with peptide 
loaded MHC molecules. Human CD4+ T cells recognize Mtb-infected monocyte 
derived dendritic cells (MDDC), but that recognition, assessed via IFNγ production, 
largely derives from the activation effects of the IL-12 and IL-18 secreted by the 
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infected MDDCs [164]. Detecting TCR-dependent, cognate recognition is 
important because this leads to delivery of cytotoxic granules such as granzyme 
through the pore forming actions of perforin [165]. On the other hand, cytokine-
activated T cells can produce IFNγ [166] but cannot carry out the full spectrum of 
effector functions [167-169].  
 
CD4+ T cell recognition of Mtb-infected cells 
Given the importance of CD4+ T cells during Mtb infection, it is logical to 
assume that the CD4+ T cells recognize Mtb-infected cells. Indeed, experiments 
have shown that CD4+ T cells must recognize infected cells in order to reduce 
bacterial burden [170].  
Studies supporting CD4+ T cell recognition often examines IFNγ, IL-2, 
proliferation, and/or bacterial burden control. Bone marrow derived macrophages 
(BMDM) infected with a virulent strain of Mtb, H37Rv, trigger Ag85b-specific 
hybridoma BB7 T cells to produce small amount of IL-2, and this production 
increases in the presence of autophagy-inducing agent rapamycin [171, 172]. Co-
culture of BB7 T cells with either untreated or IFNγ-activated BMDMs that are 
infected with H37Ra or BCG also leads to IL-2 production [173-175]. Polyclonal 
CD4+ T cells from infected mice produce IFNγ and reduce bacterial growth upon 
co-culture with BMDMs and BMDCs infected with Erdman, another virulent Mtb 
strain [76, 78, 80]. Both naïve polyclonal CD4+ T cells and polyclonal CD4+ T cells 
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isolated from the lungs of infected mice produce IL-2 and IFNγ when co-cultured 
with CD11c+I-Ab+ lung DCs isolated from infected mice [176].  
  In human studies, CD4+ T cells also recognize Mtb-infected macrophages. 
Human CD4+ T cells isolated from the PBMCs of PPD+ individuals, stimulated in 
vitro with Mtb crude cell wall extract, can secrete IFNγ and reduce intracellular 
bacterial burden upon co-culture with H37Rv-infected APCs, and this effect is 
restricted to MHC class II [177]. CD4+ T cell specific to the antigen peptide 
CFP1076-85, which is derived from a dominant Mtb antigen CFP10, reduce 
intracellular bacteria in Mtb-infected cells, and this killing depends on granulysin 
and perforin [178]. However, as mentioned above, studies have shown that the 
production of IFNγ may be largely driven by IL-12 and IL-18 produced by the 
infected cells [148, 164]. TCR-dependent T cell activation is a requirement for T 
cell proliferation [179, 180]. Since human CD4+ T cells proliferate when co-cultured 
with Mtb-infected cells, we can infer that these CD4+ T cells have cognate 
recognition of Mtb-infected cells  [181, 182].  
There is also evidence that CD4+ T cells do not recognize Mtb-infected cells, 
especially when examining Mtb antigen-specific CD4+ T cells. While there is 
consensus that Mtb-infected cells present ESAT-6, the data concerning Ag85b 
presentation is more complicated [144, 145, 151, 183]. Early after infection, 
Ag85b241-256 elicits a strong CD4+ T cell response, yet this response diminishes 
after 3 weeks post infection, mostly due to a decreased production of Ag85b by 
Mtb [144]. Thus, while Ag85b241-256-specific CD4+ T cells recognize DCs from 
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infected mice 14 days post infection [184], there is little recognition of Mtb-infected 
cells in vivo by day 21 [144]. Intravital imaging of liver granulomas in infected mice 
shows that antigen-specific CD4+ T cells do not interact with the granulomas, 
suggesting a lack of recognition during later stages of infection [185]. Mtb infection 
of BALB/c mice lowers expression of the costimulatory molecule M150 on splenic 
macrophages, and Th1 T cells co-cultured with Mtb-infected BALB/c macrophages 
express lower IL-2 and proliferate less, and the phenotype is reversed when M150 
is added to the co-culture [186]. In human T cells, Mtb-infected monocytes have 
reduced DR expression, and T cells proliferate less when co-cultured with either 
Mtb-infected APCs or APCs treated with heat killed bacteria, again arguing for a 
lack of recognition [187]. Several studies further report that antigen-specific CD4+ 
T cell recognition does not occur efficiently during Mtb infection, and that this is an 
active mechanism by which Mtb evades host immunity [151, 188, 189].  
Despite the data arguing against recognition by the CD4+ T cells, cognate 
contact is important for CD4+ T cells to carry out their effector functions. Srivastava 
et al elegantly show this by using mixed bone marrow (BM) chimeric mice made 
from WT and MHC class II deficient BM [170]. Following infection, polyclonal CD4+ 
T cells suppress Mtb growth more efficiently in MHC class II-expressing cells than 
in MHC class II-deficient cells. This evidence convincingly argues that cognate 
recognition of infected cells by polyclonal CD4+ T cells limits bacterial growth.  
All these data present the reality that we do not fully understand how CD4+ 
T cells recognize Mtb-infected cells. The recognition may be dependent on the 
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antigen as well as the timing during infection. Almost all the studies mentioned 
above do not assess cognate vs. noncognate recognition, making it challenging to 
interpret whether the recognition events are of Mtb-infected cells or not. 
 
 
CD8+ T cell recognition of Mtb-infected cells 
Mature, cytolytic (CTL) CD8+ T cells migrate from the lymph node to the 
lungs to kill Mtb-infected macrophages, and this killing is evident both in vitro and 
in vivo in mice [60]. After Mtb infection of mice, antigen-specific CD8+ T cells can 
be detected in the lungs as early as 3 weeks post infection [114, 116]. Presumably, 
to execute their functions, CD8+ T cells must recognize those infected 
macrophages. Many studies have investigated recognition indirectly when 
examining the cytolytic effects of CD8+ T cells. These studies assess recognition 
based on the CD8+ T cells’ 1) cytolytic ability via target cell killing or CD107 
degranulation [190], 2) activation using cell surface markers such as CD69 [113, 
191] and CD25 [192], or 3) IFNγ production [192]. Backing up these studies is the 
finding that Mtb infection does not inhibit the presentation of soluble OVA proteins 
to SIINFEKL-specific RF33.70 hybridoma T cells [193]. Ex vivo polyclonal CD8+ T 
cells from infected mice can reduce bacterial burden and make IFNγ when co-
cultured with Erdman-infected BMDMs [76, 78, 80], though DCs may be better at 
presenting to CD8+ T cells than macrophages [194]. Several studies have also 
investigated recognition in BCG-infected cells. CD8+ T cells specific to the MPT64 
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antigen produce IFNγ when co-cultured with BCG-infected DCs [195]. Antigen-
specific CD8+ hybridoma T cells recognize BCG-infected cells by producing IL-2 
[196]. Finally, BCG infection of macrophages does not inhibit the presentation of 
OVA protein to OVA-specific hybridoma CD8+ T cells [197, 198]. Thus, in murine 
studies, from BCG to Mtb infections, CD8+ T cells seem to be able to produce 
cytokines and reduce bacterial burden, though it is unknown whether these actions 
are TCR-dependent or not.  
Human CD8+ T cells can recognize Mtb-infected cells, when assessed for 
the above-mentioned markers. Several Mtb antigens recognized by CD8+ T cells 
from patients have been identified, indirectly suggesting that CD8+ T cells may 
recognize Mtb-infected cells [199]. Human CD8+ T cells isolated from PPD+ 
donors’ PBMCs proliferate when incubated with Mtb antigens in the absence of 
APCs, and antibody depletion of MHC class I molecules reduces the amount of 
proliferation [192]. Monocyte derived macrophages infected with virulent and 
avirulent Mtb can be recognized, based on CTL activity or IFNγ ELISpot, by CD8+ 
T cells from TB patients, either polyclonal or clonally expanded by Mtb-peptide 
[200-204]. Cho et al have identified 3 MHC class I restricted CD8+ T cells from TB 
patients that produce IFNγ and lyse Mtb-infected macrophages [203]. CD8+ T cells 
from PBMC of human patients also can release granulysin and reduce intracellular 
bacterial burden upon co-culture with infected cells [205]. In studying MDDCs, 
multiple CD8+ T cell clones have been identified from PPD+ donors when co-
cultured with Mtb-infected MDDCs [206]. Grotzke et al demonstrate that Mtb-
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infected phagosomes are competent for presentation to two CD8+ T cell clones 
from donors, further suggesting antigen presentation to CD8+ T cells [207]. Using 
fluorescent bacteria, Lewinsohn et al show that human, CFP-10-specific CD8+ T 
cells recognize a small subset of MDDCs that are heavily infected [208]. Epithelial 
cells in the human airways can harbor Mtb, and these cells are efficiently 
recognized by CD8+ T cells based on T cell IFNγ production [209].  
There is some evidence against CD8+ T cell recognition of Mtb-infected 
cells. CD8+ T cells from BCG immunized mice do not produce IFNγ or IL-2 when 
co-cultured with BCG-infected DCs [210], nor do they reduce bacterial burden in 
vitro [211]. Schaible et al have demonstrated that the MHC class I presentation 
pathway does not sample Mtb inside the infected cell, instead, uninfected, 
bystander APCs take up apoptotic vesicles containing Mtb antigens or live Mtb and 
present them to CD8+ T cells [212].  
From the above studies, only two murine studies, which show some CTL 
activity and weak recognition by the CD8+ T cells, use MHC restriction to show that 
these processes are TCR-dependent [113, 195]. An additional study has shown 
conjugate formation between CD8+ T cells isolated from PPD+ healthy donors and 
Mtb-infected macrophages [213]. However, this study only examines the conjugate 
formation after one hour of co-culturing. Given that CD8+ T cell require sustained 
interaction with their targets to perform cytolytic actions, determining the dynamics 
of contact-dependent recognition in Mtb-infected cells requires a more continuous 
observation of conjugate formation [214]. Some of the human studies used 
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monoclonal antibody blocking to restrict the responses to only CD8+ T cells [203, 
204, 215, 216]. Overall, the CD8+ T cell recognition literature shows that there is 
recognition of Mtb-infected cells. However, murine studies deal mostly with 
polyclonal CD8+ T cells and do not focus on cognate recognition while human 
studies investigate a vast repertoire of antigens produced during Mtb infection. 
Very few studies focus on the recognition by CD8+ T cells elicited by 
immunodominant antigens.  
 
Immunodominant antigens  
During Mtb infection, immunodominant antigens are the primary targets of 
T cell responses [217]. Immunodominance arises from the observation that despite 
host APCs generating numerous, often thousands, of peptides from a pathogen, 
the majority of the T cells only respond to a handful of those peptides [218]. This 
signifies that a select few antigens cause the expansion of the majority of the T 
cell response. When a biological product of a pathogen, whether it is a piece of the 
cell wall or a secreted protein, enters the MHC class I or II presentation pathway, 
that product first gets processed, either in the phagosome or, more commonly, the 
proteasome [152]. The proteasome randomly cleaves the antigen into peptides of 
varying lengths, and some will then be loaded onto MHC class I or II molecules for 
presentation. A few of those peptides might be recognized more often or earlier 
than others during an infection, leading to a large expansion of T cells during 
priming made specific for those peptides. The sequences of the peptides 
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recognized by the T cells are immunodominant epitopes, and the antigens where 
the peptides are derived from are immunodominant antigens.  
Several immunodominant antigens have been identified in the murine TB 
model, including Ag85a, Ag85b, CFP-10, ESAT-6 and TB10.4 [219]. T cell 
responses to these antigens are also frequently detectable in Mtb-infected people, 
and these highly prevalent responses represent the basis for TB immunodiagnostic 
tests [220]. Many of these immunodominant antigens serve as components in 
vaccines, with the logical expectation that T cells specific to these 
immunodominant antigens will contain the infection before Mtb can establish a 
niche and evade host immunity [217]. Yet, vaccines based on some of these 
immunodominant antigens have largely been ineffective. MV85A, a vaccine based 
on the immunodominant antigen Ag85A and the only vaccine after BCG to go 
beyond a phase I safety trial, showed no increased efficacy as a booster for BCG-
vaccinated infants [221]. Studies examining preclinical data and memory T cell 
function have shed some light as to why vaccination may not have been efficacious 
[145, 183, 222]. However, there remains a gap of knowledge in understanding the 
effectiveness of immunodominant-antigen-elicited T cell responses. 
 
Setting the stage 
 
 This chapter introduces the topics of TB pathogenesis, immune responses 
to Mtb with specific regards to CD4+ and CD8+ T cells, immune evasion by Mtb, T 
cell recognition of Mtb infected cells, and immunodominant antigens. The main 
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themes that underlie these sections are 1) Mtb has adapted to survive despite host 
immunity, and 2) there are Mtb antigens that generates large T cell responses, but 
we do not completely understand whether these responses correlate with 
protection. The work presented in this thesis focuses on T cell responses 
generated against two immunodominant antigens, TB10.4 and Ag85b. In Chapter 
II, the recognition of infected cells by TB10.4-specific CD8+ and Ag85b-specific 
CD4+ T cells will be addressed. In Chapter III, an investigation into the mechanisms 
contributing to inefficient antigen recognition will be presented. In Chapter IV, a 
discussion of the presented data will highlight areas of improvement and raise 
questions for future investigation. The data and interpretation presented in this 
thesis will hopefully enhance our understanding of how immunodominant-antigen-
elicited T cells respond during TB and better inform future vaccine designs. 
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Abstract 
Containment of Mycobacterium tuberculosis (Mtb) infection requires T cell 
recognition of infected macrophages. Mtb has evolved to tolerate, evade, and 
subvert host immunity. Despite a vigorous and sustained CD8+ T cell response 
during Mtb infection, CD8+ T cells make limited contribution to protection. Here, we 
ask whether the ability of Mtb-specific T cells to restrict Mtb growth is related to 
their capacity to recognize Mtb-infected macrophages. 
  We derived CD8+ T cell lines that recognized the Mtb immunodominant 
epitope TB10.44-11 and compared them to CD4+ T cell lines that recognized 
Ag85b240-254 or ESAT63-17. While the CD4+ T cells recognized Mtb-infected 
macrophages and inhibited Mtb growth in vitro, the TB10.4-specific CD8+ T cells 
neither recognized Mtb-infected macrophages nor restricted Mtb growth. 
Importantly, polyclonal CD8+ T cells specific for Mtb antigens other than TB10.4 
recognized Mtb-infected macrophages in a MHC-restricted manner. As TB10.4 
elicits a dominant CD8+ T cell response that poorly recognizes Mtb-infected 
macrophages, we propose that TB10.4 acts as a decoy antigen.  
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Introduction 
 
Mycobacterium tuberculosis (Mtb), the cause of human tuberculosis (TB), 
subverts and evades host immunity [122]. Mtb subverts vesicular trafficking, 
prevents phagolysosome fusion, and replicates in an intracellular niche within 
macrophages, allowing it to evade detection by humoral immunity [130]. Mtb also 
delays the initiation and recruitment of T cell immunity to the lung, promoting the 
establishment of a persistent infection [60]. Despite these challenges, T cell 
immunity does occur and plays an essential role in controlling the infection in both 
mice and humans [60, 70, 223]. With 10 million new TB cases annually, an 
effective vaccine would offer a cost-effective way to prevent TB and attenuate this 
persistent global pandemic. Given the importance of T cells during host defense, 
strategies for TB vaccines largely aim at generating memory T cells rather than 
neutralizing antibodies. Most subunit vaccines incorporate immunodominant Mtb 
antigens, which elicit large T cell responses [217]. The expectation is that antigen-
specific T cells elicited by these immunodominant-antigen-based vaccines will 
contain the infection before Mtb can adapt to the host immune system.  
T cell recognition of Mtb-infected macrophages is fundamental to 
containment of TB infection [170]. However, even though many presume that Mtb-
infected cells present immunodominant antigens, the data validating this 
assumption is surprisingly inconsistent. For example, Ag85b241-256 elicits a CD4+ T 
cell response early after infection, but Mtb reduces Ag85b production within 3 
weeks after in vivo infection, subsequently diminishing Ag85b-specific CD4+ T cell 
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response [144]. Furthermore, Mtb has other mechanisms to evade T cell 
recognition, including dysregulating MHC class II expression and inhibiting antigen 
presentation by stimulating antigen export by the infected antigen presenting cells 
(APCs) [122, 144, 151, 185]. Whether the immunodominant antigens recognized 
by CD8+ T cells are presented by Mtb-infected macrophages remains unknown. 
Here, we investigated cognate T cell recognition of Mtb-infected macrophages by 
CD8+ T cells specific to the immunodominant antigen TB10.4. 
TB10.4 (EsxH) is an ESAT-6-like protein secreted by the ESX-3 type VII 
secretion system, important in iron and zinc acquisition, and essential for Mtb 
growth in vitro and in vivo [224, 225]. Following Mtb infection, TB10.4 is a target of 
CD4+ and CD8+ T cell responses in humans and mice [226-230]. In Mtb-infected 
mice, TB10.4 elicits immunodominant responses in both BALB/c and C57BL/6 
mice, and 30-40% of lung CD8+ T cells are specific to single epitopes (Figure 2.1) 
[226, 227]. Whether these TB10.4-specific CD8+ T cells can mediate protection is 
unclear. Adoptive transfer of TB10.4-specific CD8+ T cells into Mtb-infected, 
immunocompromised mice reduces the bacterial burden and promotes survival 
[227]. However, despite eliciting large numbers of TB10.4-specific CD8+ T cells, a 
vaccine incorporating the H-2 Kb-restricted epitope, TB10.44-11, failed to protect 
mice from Mtb infection [231]. We hypothesize that the inability of TB10.4-specific 
CD8+ T cells to mediate protection is due to inefficient recognition of Mtb-infected 
macrophages. 
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We used primary CD4+ and CD8+ T cells lines to investigate the recognition 
of Mtb-infected macrophages by T cells specific to Ag85b, ESAT-6, or TB10.4. 
Ag85b- and ESAT-6-specific CD4+ T cells recognized Mtb-infected macrophages, 
but under the same conditions, TB10-specific CD8+ T cells did not recognize 
infected macrophages or inhibit bacterial growth. This was true even upon 
examination of numerous conditions and permutations including length of 
infection, duration of T cell and macrophage co-culture, and multiplicity of infection. 
Interestingly, polyclonal CD8+ T cells specific for Mtb antigens other than TB10.4 
recognized Mtb-infected macrophages in a MHC class I-restricted manner. Thus, 
while TB10.4-specific CD8+ T cells do not recognize Mtb-infected macrophages, 
there exist other CD8+ T cells that recognize subdominant antigens presented by 
Mtb-infected cells. Based on these data, we propose that TB10.4 is a decoy 
antigen: it elicits a massive and persistent CD8+ T cell response, which cannot 
recognize Mtb-infected macrophages. Such a decoy antigen may distract the CD8 
response from focusing on subdominant antigens presented by infected cells, 
leading to evasion from host immunity. 
Moreover, it appears that this response overshadows a subdominant CD8+ 
T cell response that can recognize Mtb-infected macrophages. The ability of Mtb 
to subvert the CD8+ T cell response may explain why CD8+ T cells make a 
disproportionately small contribution to host defense compared to CD4+ T cells. 
The selection of Mtb antigens for vaccines has focused on antigens that generate 
immunodominant responses. We propose that establishing whether vaccine-
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elicited, Mtb-specific T cells recognize Mtb-infected macrophages could be a 
useful criterion for preclinical vaccine development. 
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Results 
 
TB10.4-specific CD8+ T cells dominate the pulmonary CD8+ T cell response 
during Mtb infection 
We first examined if the Mtb antigen TB10.4 elicited a large CD8+ T cell 
response. 6 weeks post aerosol infection of C57BL/6 mice, 35% of total lung CD8+ 
T cells were TB10.44-11-tetramer positive (Figure 2.1). This confirms findings from 
previously published data [227, 231]. 
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Figure 2.1. TB10.44-11-tetramer positive CD8+ dominates the pulmonary CD8+ 
T cell response during Mtb infection in C57BL/6 mice. Representative flow plot 
showing the percent of TB10.44-11-tetramer positive CD8+ T cells among lung cells 
isolated from mice infected with Erdman via the aerosol route 6 weeks post-
infection. 
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TB10.4-specific CD8+ and Ag85b-specific CD4+ T cell lines sensitively 
recognize their cognate antigens 
 To study T cell recognition of Mtb-infected macrophages, we established 
antigen-specific T cell lines, which unlike T cell hybridomas, facilitate the study of 
T cell function as well as recognition. The TB10.44-11-specific CD8+ T cell line, 
referred hereafter as TB10Rg3, has a distinct TCR cloned originally from TB10.44-
11-tetramer+ CD8+ T cells isolated from infected mice and expressed in retrogenic 
mice [227]. The Ag85b240-254-specific CD4+ T cell line, referred hereafter as P25 
cells, was derived from P25 TCR transgenic mice [232]. To confirm their antigen-
specificity, we co-cultured the P25 or TB10Rg3 T cells with thioglycolate-elicited 
peritoneal macrophages (TGPMs) pulsed with or without their cognate peptides 
and then measured their expression of CD69 and Nur77. While both CD69 and 
Nur77 are T cell activation markers, increases in Nur77 expression indicate TCR-
mediated activation more specifically [163, 233]. After co-culture with TGPMs 
pulsed with Ag85b241-256 peptide, Nur77 expression by P25 cells peaked after 2 
hours (Figure 2.2a, b), while CD69 expression continued to increase (Figure 2.2c, 
d). TB10Rg3 T cells exhibited similar Nur77 and CD69 expression patterns after 
their co-culture with TGPMs pulsed with the TB10.44-11 peptide (IMYNYPAM) but 
not with a control peptide (IMANAPAM) (Figure 2.2e-h). Since the increase in 
Nur77 expression was transient, we next tested whether CD69 and IFNγ could be 
useful markers of antigen recognition for longer experiments. During 72 hours of 
co-culture with peptide-pulsed TGPMs, P25 and TB10Rg3 T cells continued to 
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express CD69 and secreted IFNγ in a peptide dose-dependent manner (Figure 
2.2i-l). These experiments show that P25 and TB10Rg3 T cells can recognize their 
cognate antigens presented by TGPMs, both in short-term and long-term co-
culture assays. 
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Figure 2.2. TB10.4-specific CD8+ (TB10Rg3) and Ag85b-specific CD4+ (P25) 
T cells both recognize their cognate peptides. (a) Representative histogram of 
Nur77 expression in P25 T cells after 2 hours of co-culture with macrophages and 
(b) time course of Nur77 MFI in P25 T cells. (c) Representative histogram of CD69 
in P25 T cells after 2 hours of co-culture with macrophages and (d) time course of 
CD69 MFI in P25 T cells. (e) Representative histogram of Nur77 in TB10Rg3 T 
cells after 2 hours of co-culture and (f) time course of Nur77 MFI in TB10Rg3 T 
cells. (g) Representative histogram of CD69 in TB10Rg3 T cells at 2 hours of co-
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culture with macrophages and (h) time course of CD69 MFI in TB10Rg3 T cells. (i) 
CD69 MFI and (j) IFNγ production by P25 T cells after 72 hours of co-culture. (k) 
CD69 MFI and (l) IFNγ production by TB10Rg3 cells after 72 hours of co-culture. 
MFI, mean fluorescence intensity; m, macrophage. 
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Ag85b-specific CD4+ T cells, but not TB10.4-specific CD8+ T cells, restrict 
intracellular bacterial replication 
Given that a primary function of T cells during Mtb infection is to restrict 
bacterial growth, we determined whether these T cell lines could limit intracellular 
mycobacterial growth in vitro. We infected TGPMs with H37Rv, a virulent Mtb 
strain that expresses both TB10.4 and Ag85b in vitro [229, 234]. To assess 
whether any bacterial growth inhibition observed was dependent on cognate 
recognition, we infected both MHC-matched (i.e., H-2b) and mismatched (i.e., H-
2k) macrophages. T cells were added on day 1 post-infection, and the number of 
colony forming units (CFU) was assayed 96 hours later. In the absence of T cells, 
Mtb grew significantly (p<0.01) (Figure 2). P25 T cells significantly inhibited 
intracellular bacterial growth in H37Rv-infected TGPMs (p<0.0001). Addition of 
Ag85b peptide to the infected macrophages did not further enhance the ability of 
P25 T cells to inhibit bacterial growth, suggesting that their activation was maximal. 
As expected, P25 T cells only inhibited bacterial growth in MHC-matched 
macrophages, indicating that growth inhibition mediated by T cells required 
cognate recognition under these conditions. 
In contrast, TB10Rg3 T cells did not inhibit bacterial growth (Figure 2.3). We 
considered whether the inability of TB10Rg3 to inhibit bacterial growth was due to 
a lack of recognition of the infected macrophages or a defect in the T cells’ effector 
functions. When Mtb-infected TGPMs were pulsed with the TB10.44-11 peptide for 
one hour prior to adding the T cells, TB10Rg3 T cells significantly reduced bacterial 
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growth (p<0.0001) (Figure 2.3). We wondered whether a TCR with stronger affinity 
might be more effective at inhibiting bacterial growth. We derived another TB10.44-
11-specific CD8+ T cell line, referred hereafter as TB10Rg4 T cells, that has a higher 
affinity than TB10Rg3 based on previous publication [227]. Co-culture of Mtb-
infected macrophages with TB10Rg4 T cells also did not lead to a significant 
reduction in bacterial burden, and, similar to TB10Rg3 T cells, the TB10Rg4 T cells 
did significantly inhibit bacterial growth when the infected macrophages were 
pretreated with the TB10.4 peptide (Figure 2.3).  
Thus, under the same conditions where P25 T cells significantly suppressed 
intracellular Mtb growth in a MHC-restricted manner, TB10Rg3 and TB10Rg4 T 
cells failed to inhibit bacterial growth. Since TB10Rg3 and TB10Rg4 T cells did 
inhibit bacterial growth when their cognate peptide was added to Mtb-infected 
macrophages, we conclude that both T cells could express the effector function 
required to restrict intracellular bacterial growth; however, they simply did not 
recognize Mtb-infected macrophages.  
 
 
 
 
 
 
 
56 
 
 
 
Figure 2.3. Ag85b-specific CD4+ T cells, but not TB10.4-specific CD8+ T cells, 
inhibit bacterial growth in vitro. Matched (H-2b) or mismatched (H-2k) 
macrophages were infected with H37Rv for 2 hours, and then, one day post-
infection, T cells were added. CFU were determined 4 days later. Separately, 
TB10.4 or Ag85b peptide was added to Mtb-infected (H-2b) macrophages, and 
then T cells were added. Results are representative of at least three experiments. 
Statistical testing was by one-way ANOVA, using the Dunnett posttest compared 
to d5. *, #, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.0001. φ, macrophages. 
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Ag85b-specific CD4+ T cells, but not TB10.4-specific CD8+ T cells, recognize 
Mtb-infected macrophages.  
To further investigate TB10Rg3 and P25 T cells recognition of Mtb-infected 
cells, we next investigated the kinetics of Mtb antigen presentation. After Mtb 
infection, TGPMs were cultured for various lengths of time before adding the T 
cells. To assay antigen presentation, we added the T cells for two hours and then 
measured Nur77 and CD69 (see Figure 2.2. for kinetics). When added immediately 
after infection (i.e., day 0), P25 T cells recognized Mtb-infected macrophages 
based on the induction of Nur77 and CD69 (Figure 2.4a, b). Under these 
conditions, there was no increase in Nur77 or CD69 expression by TB10Rg3 T 
cells (Figure 2.4c, d). To assess whether increased TCR affinity of TB10.4 might 
lead to better recognition, we examined TB10Rg4 T cells. Similar to TB10Rg3, the 
TB10Rg4 T tells did not show increased Nur77 or CD69 expression (Figure 2.4e, 
f). We next chose later time points, which might allow Mtb to adapt to the 
intracellular environment and potentially let the TB10.4 antigen accumulate. 
TB10Rg3 T cells were added to infected macrophages on days 1, 3, or 5 post-
infection. Again, we did not observe any increase in Nur77 or CD69 expression 
(Figure 2.4g, h). As a control for T cell health and function, we co-cultured TB10.44-
11-peptide-pulsed-, uninfected-macrophages with either TB10Rg3 or TB10Rg4 T 
cells and observed significant increases in their Nur77 and CD69 expression 
(Figure 2.4).  
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Despite assessing recognition on multiple days, we considered whether the 
short assay period (i.e. 2 hours) might not detect recognition of Mtb-infected 
macrophages by TB10Rg3 T cells, especially if presentation of TB10.4 is inefficient 
or asynchronous. Therefore, we used IFNγ production as a cumulative indicator of 
T cell activation during a 72-hour co-culture experiment. Since cytokine-driven 
activation (e.g., IL-12, IL-18) can stimulate IFNγ production by T cells 
independently of TCR signaling, we used MHC-matched (H-2b) or mismatched (H-
2k) TGPM to assess cognate recognition [55, 161-163]. Over the first 3 days post 
infection (i.e., d0-d3), as the infectious dose (MOI, multiplicity of infection) 
increased, more IFNγ was measured when the P25 T cells were co-cultured with 
MHC-matched, Mtb-infected TGPMs compared to when they were co-cultured with 
MHC-mismatched, Mtb-infected TGPMs (Figure 2.4i). In contrast, TB10Rg3 as 
well as TB10Rg4 T cells did not produce IFNγ when co-cultured with Mtb-infected 
TGPMs (Figure 2.4j, k). Interestingly, in 2 out of 3 experiments, TB10Rg4 did show 
a slight increase in IFNγ production as the MOI increased (Figure 2.4k). However, 
while this increase was MHC restricted, it was not a significant increase when 
analyzed by two-way ANOVA with Sidak posttest. This reflects that increased 
affinity leads to a better T cell response, but it is still much smaller compared to 
that of the P25 T cells. We also investigated whether adding the T cells at a later 
time (i.e., d3) might lead to better recognition. Over the latter 3 days of infection 
(i.e., d3 to d6), P25 T cells produced significant IFNγ while both TB10Rg3 and 
TB10Rg4 T cells did not (Figure 2.4l-n). Of note, TB10Rg4 did show a trend in 
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increased IFNγ production, but the trend was not consistent or specific in 2 
experiments. Together, these data show that TB10.4-specific CD8+ T cells do not 
produce IFNγ when co-cultured either during early or late infection.  
As before, TB10Rg3 and TB10Rg4 T cells produced IFNγ when co-cultured 
with uninfected macrophages pulsed with the TB10.44-11 peptide (Figure 2.4j, k). 
These data show that, regardless of the time point of T cell addition or the length 
of co-culture, P25 T cells, but not TB10Rg3 or TB10Rg4 T cells, recognized Mtb-
infected macrophages, based on their increased Nur77 and CD69 expression as 
well as their IFNγ production.  
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Day0 to Day3 post infection:  
 
 
 
 
Day3 to Day6 post infection: 
 
 
 
 
 
Figure 2.4. Ag85b-specific CD4+ T cells, but not TB10.4-specific CD8+ T cells, 
recognize Mtb-infected macrophages. (a-d) T cells were co-cultured with 
peptide-pulsed, Mtb-infected, or uninfected macrophages for 2 hours. (a) 
Representative histogram of Nur77 expression in P25 T cells and the normalized 
Nur77 MFI. (b) Representative histogram of CD69 expression in P25 T cells and 
the normalized CD69 MFI. (c) Representative histogram of Nur77 in TB10Rg3 T 
cells and the normalized Nur77 MFI. (d) Representative histogram of CD69 
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expression in TB10Rg3 T cells and the normalized CD69 MFI. (e) Representative 
histogram of Nur77 in TB10Rg4 T cells and the normalized Nur77 MFI. (f) 
Representative histogram of CD69 expression in TB10Rg4 T cells and the 
normalized CD69 MFI. (g-h) TB10Rg3 T cells were co-cultured with uninfected, 
peptide-pulsed, or Mtb-infected macrophages for 2 hours on d1, d3, and d5 post 
infection. Normalized expression of (g) Nur77 or (h) CD69 by TB10Rg3 T cells. 
P25 (i), TB10Rg3 (j), or TB10Rg4 (k) T cells were co-cultured with uninfected, 
peptide-pulsed, or Mtb-infected macrophages, and IFNγ production was measured 
after 72 hours from d0 to d3 post infection. P25 (l), TB10Rg3 (m), or TB10Rg4 (n) 
T cells were co-cultured with uninfected, peptide-pulsed, or Mtb-infected 
macrophages, and IFNγ production was measured after 72 hours from d3 to d6 
post infection.   Figures are representative of at least 5 (a-f, TB10Rg3), 3, (a-f, 
TB10Rg4), 2 (a-f, P25, and l-n), or 3 (g-k) experiments. Statistical analysis was 
done by one-way ANOVA with Dunnett posttest (a-d) or two-way ANOVA with 
Sidak posttest (g-h). *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.0001. φ, 
macrophages. 
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TB10Rg4 CD8+ T cells recognize Mtb-infected dendritic cells. 
 Dendritic cells are critical in priming CD8 T cells during Mtb infection [61]. 
DCs are known to be better antigen presenters than macrophages, even during 
Mtb infection [80, 194]. Interestingly, by 4 weeks post infection, CD11b+/hiCD11c+/hi 
myeloid DCs represent a high percentage of infected cells in the lungs of infected 
mice, but, by 10 weeks post infection, CD11b+/loCD11c-/lo recruited 
monocytes/macrophages are the dominant infected macrophages [235]. We next 
investigated whether Mtb-infected dendritic cells may lead to recognition by the 
TB10Rg3 and TB10Rg4 T cells. After 72 hours of co-culture, TB10Rg3 T cells did 
not consistently produce significant amount of IFNγ as significant IFNγ production 
was measurable in only 2 out of 4 experiments. However, TB10Rg4 T cells, which 
has a higher affinity than TB10Rg3 T cells, consistently produced IFNγ, as did P25 
T cells, in a MHC-restricted manner (Figure 2.5a, b). This shows that BMDCs can 
present TB10.4 to TB10.4-specific CD8 T cells, and that affinity may be an 
important contributing factor for recognition of the immunodominant TB10.4 
antigen.  
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Figure 2.5. Ag85b-specific CD4+ T cells and TB10.4-specific CD8+ T cells 
recognize Mtb-infected bone marrow derived dendritic cells (BMDCs). P25 
(a) or TB10Rg4 (b) T cells were co-cultured with uninfected or Mtb-infected 
BMDCs, and IFNγ production was measured after 72 hours. Figures are 
representative of 3 experiments. Statistical analysis was done by two-way ANOVA 
with Sidak posttest. *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.0001. φ, 
macrophages. 
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TB10.4-specific CD8+ T cells do not recognize lung cells from Mtb-infected 
mice.  
During in vivo infection, Mtb infects a variety of myeloid cells, and this 
diversity changes over the course of the infection [236-238]. We considered that 
lung myeloid cells from Mtb-infected mice are more physiologically relevant than 
TGPMs. Thus, we isolated MHC class II+ lung cells from Erdman-infected, RAG-1-
/-  mice 4 weeks post infection and tested their ability to present Mtb antigens to 
TB10Rg3 T cells. We used RAG-1-/- mice because of the possibility that CD8+ T 
cells in the lungs of Mtb-infected, wild type mice may recognize and eliminate any 
lung cells presenting the TB10.4 antigen. Since Mtb downregulates Ag85b 
expression by 3 weeks post infection [144, 145], we used an ESAT-6-specific CD4+ 
T cell line we derived from C7 transgenic mice, which we refer to as C7 T cells 
[183, 239]. The immunodominant antigen ESAT-6 retains high levels of expression 
throughout infection and elicits a dominant CD4+ T cell response in C57Bl/6 mice 
[145]. Due to the difficulty in obtaining large numbers of MHC class II+ cells from 
uninfected, RAG-1-/- mice, we used TGPMs from age-matched, RAG-1-/- mice as 
a source of uninfected, inflammatory macrophages. Cognate recognition is a 
requirement for T cell proliferation [179, 180], thus we examined the proliferative 
abilities of these T cells after co-culture with the lung myeloid cells. We stained C7, 
TB10Rg3, TB10Rg4 T cells with 5uM of the proliferation dye eFluor450 
(eBioscience) before co-culturing them with the lung myeloid cells. After 72 hours, 
we measured their proliferation. C7 T cells proliferated extensively when co-
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cultured with the infected lung myeloid cells but not when co-cultured with 
uninfected TGPMs (Figure 2.6a, b). In contrast, TB10Rg3 T cells did not proliferate 
when co-cultured with the lung myeloid cells (Figure 2.6c, d). To assess whether 
TB10Rg3 T cells could proliferate if TB10.4 was present, we pulsed the lung APCs 
with the TB10.44-11 peptide for 1 hour before adding the TB10Rg3 T cells. As 
predicted, TB10Rg3 T cells proliferated after 72 hours of co-culture with peptide-
pulsed, lung myeloid cells (Figure 2.6c, d). Despite having a higher affinity, 
TB10Rg4 T cells also did not proliferate after the co-culture (Figure 2.6e, f) 
 We considered the possibility that Mtb in lung myeloid cells may not grow 
well in vitro, leading to altered antigen abundance that could affect T cell 
recognition. To address this possibility, we measured the bacterial burden in the 
lung myeloid cells. There was a 3-fold increase in the bacterial numbers between 
the beginning (d1) and the end (d4) of the experiment, indicating that the bacteria 
remained viable (Figure 2.6g). Together, these data indicate that, under the 
conditions in which C7 T cells recognized lung myeloid cells from Mtb-infected 
mice, TB10Rg3 and TB10Rg4 T cells did not recognize these lung myeloid cells. 
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Figure 2.6. TB10.4-specific CD8+ T cells do not recognize lung APCs from 
infected mice. (a-d) T cell proliferation after coculture with lung APC from infected 
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mice, with or without cognate peptide, or uninfected TGPM, based on eFluor450 
fluorescence dilution after 72 hours. Representative flow plot (a) and quantification 
(b) of C7 T cell proliferation. Representative flow plot (c) and quantification (d) of 
TB10Rg3 T cell proliferation. Representative flow plot (e) and quantification (f) of 
TB10Rg4 T cell proliferation. (g) Bacterial burden in the lung APCs during in vitro 
culture over the course of the experiment in the absence of T cells. Representative 
of 4 (TB10Rg3 or TB10Rg4) or 2 (C7) similar experiments.  
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Polyclonal, TB10.44-11-tetramer negative CD8+ T cells from the lungs of Mtb-
infected mice recognize infected macrophages. 
Along with the previous finding that TB10.44-11-specific CD8+ T cells make 
up ~40% of total lung CD8+ T cells during infection (2.1 Figure) [227], our finding 
that TB10Rg3 and TB10Rg4 T cells do not recognize Mtb-infected macrophages 
suggests that TB10.4 may be a decoy antigen. This raises the question whether 
the inability to recognize Mtb-infected macrophages is a general feature of the 
CD8+ T cell response to Mtb, or if this is a unique feature of TB10.4-specific CD8+ 
T cells. Therefore, we determined whether polyclonal CD8+ T cells from the lungs 
of infected mice could recognize Mtb-infected macrophages. We carried out 
aerosol infection of C57BL/6 mice with the virulent Mtb strain Erdman, and, 6-8 
weeks post infection, we purified polyclonal CD4+ or CD8+ T cells from their lungs 
and co-cultured them with Mtb-infected macrophages. After 72 hours of co-culture, 
polyclonal CD4+ T cells produced high amounts of IFNγ in a MHC-restricted 
manner (Figure 2.7a). Interestingly, polyclonal CD8+ T cells also produced IFNγ in 
a MHC-restricted manner when co-cultured with Mtb-infected macrophages 
(Figure 2.7b). These results indicate that other antigen-specific CD8+ T cells 
recognizing Mtb-infected macrophages do exist, and infected TGPMs can present 
Mtb antigens to CD8+ T cells. However, based on the high abundance of TB10.4-
specific CD8+ T cells post infection (Figure 2.1), the non-TB10.4-specific, Mtb-
specific CD8+ T cells may be dwarfed by the dominant TB10.4-specific CD8+ T 
cells.  
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To better assess whether the IFNγ production by polyclonal CD8+ T cells 
arose predominantly from non-TB10.4-specific CD8+ T cells, we used the TB10.44-
11-tetramer to separate TB10.4-specific and non-TB10.4-specific, polyclonal CD8+ 
T cells from the lungs of infected mice. After 72-hour co-culture with Mtb-infected 
macrophages, TB10.44-11-tetramer negative CD8+ (non-TB10.4-specific CD8+) T 
cells produced significantly higher IFNγ compared to that of uninfected control 
(p<0.005), and the production was MHC class I restricted (Figure 2.7c). In contrast, 
TB10. 44-11-specific CD8+ T cells produced IFNγ in a non-MHC-restricted manner 
during co-culture with both uninfected and Mtb-infected macrophages (Figure 
2.7d). We cannot exclude the possibility that the tetramer isolation might have 
inadvertently activated the TB10.44-11-specific CD8+ T cells. Nevertheless, these 
data show that polyclonal, TB10.44-11-tetramer negative CD8+ T cells recognized 
Mtb-infected macrophages, supporting the notion of a subdominant T cell 
response that may be effective at detecting Mtb. 
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Figure 2.7. Polyclonal CD8+ T cells from the lungs of Mtb-infected mice 
recognize infected macrophages. IFNγ production by polyclonal CD4+ (a) or 
CD8+ (b) T cells after co-culture with either MHC-matched (H-2b) or MHC-
mismatched (H-2k), Mtb-infected macrophages. IFNγ production by TB10.44-11-
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tetramer-depleted (c) or tetramer-enriched (d) polyclonal CD8+ T cells after co-
culture with either MHC-matched (H-2b) or MHC-mismatched (H-2k), Mtb-infected 
macrophages. Data is representative of at least 2 experiments. Statistical testing 
by a two-tailed, unpaired Student’s T test. *, p<0.05; **, p<0.01; and ***, p<0.005. 
ɸ, macrophages. 
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Discussion 
 A complexity in defining T cell recognition is distinguishing cognate from 
non-cognate recognition. T cell IFNγ production, a common readout for 
recognition, can be stimulated by IL-12 and IL-18, two cytokines secreted by Mtb-
infected cells [55, 161-163]. Even cognate recognition does not always signify 
recognition of infected cells. Uninfected macrophages and dendritic cells (DCs) 
can acquire exosomes, soluble proteins, apoptotic vesicles or necrotic debris 
containing non-viable bacilli or its antigens and present these to T cells [151, 240-
242]. This detour pathway allows T cells to be activated by uninfected DCs [212, 
240]. Thus, T cell recognition of infected macrophages, which is central to our 
fundamental paradigm of TB pathogenesis, remains poorly defined.  
 Our study advances the understanding of T cell recognition of Mtb-infected 
cells. By focusing on TCR-mediated recognition, our data show that T cells specific 
to immunodominant antigens vary in their ability to recognize Mtb-infected 
macrophages. Despite being a persistent and dominant population of CD8+ T cells 
in the lungs of Mtb-infected mice, TB10.44-11-specific CD8+ T cells do not recognize 
Mtb-infected macrophages. While we primarily used TGPMs, which have been 
used to model human macrophages [135, 243], we also showed that TB10.4-
specific CD8+ T cells also failed to recognize lung APCs from infected mice. 
Importantly, concurrent with our analysis of CD8+ T cells, we systematically 
assessed recognition of Mtb-infected macrophages by Ag85b-specific (i.e., P25) 
and ESAT-6-specific (i.e., C7) CD4+ T cells. Both recognized Mtb-infected 
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macrophages and inhibited bacterial growth (here and [183]). Thus, under 
conditions that activated Mtb-specific CD4+ T cells, no activation of TB10.4-specific 
CD8+ T cells occurred. This finding has many implications, among which the most 
important is that not all Mtb-specific T cells recognize Mtb-infected macrophages. 
Ag85b is an immunodominant antigen with an epitope recognized by CD4+ 
T cells in C57BL/6 mice. In vivo data shows that Ag85b-specific CD4+ T cells can 
recognize Mtb-infected cells early during infection; however, recognition 
decreases after infection is established [89, 144, 184, 185, 244]. The inability of 
Ag85b-specific CD4+ T cells to efficiently recognize Mtb-infected bone-marrow 
derived macrophages (BMDMs) or bone-marrow derived dendritic cells (BMDCs) 
stems from a combination of reduced Ag85b expression by Mtb and because 
infected cells actively export Ag85b into the extracellular milieu [144, 151]. In our 
experiments, we found that P25 T cells recognized Mtb-infected macrophages and 
inhibited bacterial growth in a MHC-restricted manner. A difference between the 
studies is the duration of macrophage and T cell co-culture. Grace et al examined 
16-24 hours and found a lack of recognition, whereas our assays focused on 72-
96 hours and detected recognition. Moreover, it is unknown whether Mtb-infected 
cells still exported antigens after the initial 24 hours of infection. Furthermore, the 
exported Ag85b could be taken up by infected cells during longer co-cultures, 
leading to their recognition by T cells. A recent study by Lai et al have found that 
Mtb-infected DCs can lead to the proliferation of P25 T cells [184], consistent with 
our findings that P25 T cells can recognize Mtb-infected macrophages. Finally, it 
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is possible that cognate recognition of uninfected cells that present Ag85b can 
activate CD4+ T cells in a TCR-mediated manner, inducing IFNγ and indirectly 
controlling Mtb replication in macrophages. Nonetheless, under conditions that 
activate Mtb-specific CD4+ T cells, we could not observe activation of TB10.4-
specific CD8+ T cells.  
 These results led us to re-examine the evidence that CD8+ T cells recognize 
infected cells. In our evaluation of the literature, among the best evidence is: (1) 
direct ex vivo recognition of Mtb-infected macrophages and DC by CD4+ and CD8+ 
T cells [80, 176, 194, 245]; (2) murine T cells’ cytolytic activity (CTL) of MTb-
infected cells [76, 78, 113]; (3) human CD8+ T cells that recognize Mtb-infected 
DC [208, 216, 246]. However, these data have limitations. The murine studies 
rarely demonstrated cognate recognition, and the frequencies were lower than 
expected. The human studies were only done using DC and not macrophages and 
used a high MOI, raising concerns about death of infected cells and presentation 
of nonviable antigen. Nevertheless, these studies are consistent with the idea that 
CD8+ T cells recognize infected cells, but the frequency that recognize infected 
macrophages might be lower than we previously expected. Such a finding might 
explain why CD8+ T cells make a disproportionately small contribution to host 
defense, even though Mtb infection elicits a robust CD8 T cell response. 
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Abstract 
 
T cells specific to immunodominant antigens are generated during Mtb 
infection, yet whether they recognize Mtb-infected macrophages is debatable. We 
have previously shown that TB10.4-CD8+ T cells do not efficiently recognize Mtb-
infected macrophages, whereas the Ag85b-specific CD4+ T cells do. We also 
found that there are polyclonal CD8+ T cells that recognize Mtb-infected 
macrophages, yet we do not know which antigens are presented. These data 
suggest that there may be a unique mechanism that prevents the presentation of 
TB10.4 during infection.  
Here, we investigate the lack of recognition by the TB10.4-specific CD8+ T 
cells. First, we examined whether Mtb may interfere with antigen presentation. We 
found that infection with Mtb did not inhibit expression of MHC I or MHC II 
molecules, nor did it interfere with presentation of OVA-bound magnetic beads. 
Moreover, we also examined whether the TGPMs could process and present 
TB10.4 whole protein during an infection. Listeria monocytogenes expressing 
TB10.4 protein was successfully recognized by TB10.4-specific CD8+ T cells after 
infection in TGPMs. Over-expression of TB10.4 in Mtb also did not result in better 
recognition by TB10.4-specific CD8+ T cells. Finally, we investigated whether Mtb 
may specifically inhibit the presentation of TB10.4. TB10.4-specific CD8+ T cells 
recognized macrophages pulsed with irradiated Mtb, indicating that macrophages 
can efficiently cross-present the TB10.4 protein and raising the possibility that 
viable bacilli might suppress cross-presentation. 
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Introduction 
 
Mycobacterium tuberculosis has evolved many mechanisms of evading the 
host immune system. Other than preventing phagolysosomal fusion, Mtb also 
interferes with innate microbicidal activities of the macrophages [131] [132] and 
preferentially leads to the necrosis of the infected cells [135] [136]. Both human 
and mouse studies have shown that Mtb infection prevents the upregulation of 
IFNγ-induced MHC class II expression [148, 149], and the Mtb 19-kDa lipoprotein 
is responsible for this interference [122]. Mtb can also selectively turn down its 
expression of certain antigens so that antigen-specific T cells cannot recognize the 
infected cells late during infection [144]. Mtb also evades adaptive immunity by 
delaying T cell priming and recruitment, in both mice and human studies [60] [141, 
142]. These data present a complicated host-pathogen interaction that favors the 
survival of Mtb within its host.  
 We have previously shown that Mtb antigen-specific CD8+ and CD4+ T cells 
differed in their capacity to recognize Mtb-infected cells. In a Mtb-infected, 
C57BL/6 mouse, TB10.4-specific CD8+ T cells dominate the CD8+ T cell response 
in the lung (Figure 2.1). Ag85b-specific CD4+ T cells also dominate the CD4+ T cell 
response in the lung during infection of C57BL/6 mice [247]. Ag85b-specific CD4+ 
T cells recognized Mtb-infected macrophages and reduced bacterial burden 
(Figures 2.3-2.5). However, TB10.4-specific CD8+ T cells did not recognize Mtb-
infected macrophages (Figures 2.3-2.4), though higher affinity TB10.4-specific 
CD8+ T cells did recognize Mtb-infected DCs (Figure 2.5). The in vitro macrophage 
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study results were confirmed using ex vivo lung APCs, which also did not trigger 
recognition by the TB10.4-specific CD8+ T cells (Figure 2.6). Yet, there are other 
antigens presented by the infected macrophages as polyclonal, non-TB10.4-
specific CD8+ T cells recognized those macrophages (Figure 2.7). These results 
suggest a unique environment in the infected macrophage that prevents 
successful antigen presentation of TB10.4.  
 We took several different approaches to investigate the lack of antigen 
recognition of TB10.4 during infection. We found that the infected macrophages 
retained their antigen presentation ability during infection (i.e. no decrease in MHC 
I or II expression and being able to present other antigens). Next, we found that 
TB10.4-specific CD8+ T cells recognized macrophages infected with recombinant 
Listeria monocytogenes expressing TB10.4, but only if the bacilli could escape into 
the cytosol. However, overexpressing TB10.4 in Mtb did not confer recognition. 
Importantly, macrophages pulsed with irradiated bacteria, as well as activated, 
Mtb-infected macrophages, efficiently cross-presented TB10.4 to CD8+ T cells, 
suggesting that live Mtb actively inhibited presentation. 
 Together, these data suggest that Mtb does not interfere with the antigen 
presentation ability of the macrophage on a whole cell scale. Live infection may 
impair the presentation of TB10.4 specifically. The impairment of this presentation 
may help Mtb evade T cell immunity as 35% of the CD8+ T cells, which are TB10.4-
specific, cannot recognize the Mtb-infected macrophages.  
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Results 
 
Mtb infection does not significantly impair MHC class I and II expression of 
macrophages. 
We investigated whether Mtb may inhibit MHC class I expression by 
infected TGPMs. Mtb and TLR2 agonists inhibit IFNγ-induced MHC class II 
expression by bone marrow derived macrophages, and the mycobacterial PPE38 
protein can inhibit MHC class I expression in RAW264.7 macrophages and TGPMs 
infected with Mycobacterium smegmatis [149, 248]. Therefore, we asked whether 
Mtb impaired MHC class I expression in our in vitro infection system, especially 
since the TGPMs were not pre-activated with IFNγ prior to infection. We measured 
MHC class I and II expression by macrophages on each of the five days following 
infection. At baseline, uninfected TGPMs expressed high MHC class I, and Mtb 
infection did not alter MHC class I expression compared to the baseline (Figure 
3.1a, c; solid lines). Although IFNγ pretreatment of macrophages led to an increase 
in MHC class I expression in uninfected TGPMs, infected TGPMs did not achieve 
the same peak levels (Figure 3.1a, c; dotted lines). As expected, the regulation of 
MHC class II was more sensitive to IFNγ. Uninfected TGPMs expressed low 
baseline levels of MHC class II (Figure 3.1b, d; solid lines). IFNγ pretreatment 
resulted in a >100-fold increase in MHC class II median fluorescence intensity 
(MFI) in the uninfected TGPMs, which peaked on day 3 with a >2000-fold increase 
over the baseline (Figure 3.1b, d; dotted lines). Mtb-infection alone did not 
significantly affect MHC class II expression, and consistent with previous studies, 
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Mtb significantly impaired the induction of MHC class II by IFNγ pretreatment 
(Figure 3.1b, d). These data show that in our in vitro infection model, in which the 
TGPMs were unstimulated, Mtb infection did not inhibit class I and II MHC 
expression. Importantly, the differences in MHC class I or class II expression by 
Mtb-infected macrophages cannot explain why P25 T cells, but not TB10Rg3 or 
TB10Rg4 T cells, recognized infected macrophages. 
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Figure 3.1. Mtb infection does not significantly impair MHC class I and II 
expression of macrophages. (a-b) MHC class I and II expression by Mtb-
infected-macrophages. Representative histograms and fold-change of MHC class 
I (a, c) or class II (b, d) expression on infected cells. Data is representative of 3 
experiments. Statistical testing by one-way ANOVA with Dunnett posttest. *, 
p<0.05; **, p<0.01; and ***, p<0.005.  
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Mtb infection does not interfere with global presentation of antigens. 
 Mtb can interfere with a series of host immune signaling pathways in the 
macrophage in order to survive. In 1996, Mazzaccaro et al found that feeding 
soluble OVA protein to Mtb-infected BMDMs led to production of IL-2 by SIINFEKL-
specific, MHC I-restricted CD8+ T cell hybridoma, RF33.70 [193]. However, more 
recent studies have suggested that live Mtb infection may impede the presentation 
of antigens [210-212]. Our data previously showed that polyclonal CD8+ T cells 
from the lungs of infected mice recognized Mtb-infected macrophages, suggesting 
that live Mtb infection does not impede antigen presentation of all Mtb antigens. 
Nonetheless, we thought to test whether Mtb infection may interfere with antigen 
presentation within the entire infected cell.  
 TGPMs were either uninfected, uninfected treated with γ-irradiated Mtb (i.e. 
dead bacteria), or infected with live Mtb. All samples were then treated with either 
the SIINFEKL peptide or a titration of OVA-bound magnetic beads (a generous gift 
from Dr. Kenneth Rock, University of Massachusetts, Worcester, MA) and then co-
cultured with SIINFEKL-specific RF33.70 CD8+ T cells, which is a MHC class I 
restricted [249]. After 24 hours of co-culture, we found that the RF33.70 T cells 
produced IL-2 when co-cultured with any of the three different macrophage 
populations, regardless of the titration of the OVA-bound beads (Figure 3.2). At the 
highest concentration of OVA-bound beads (i.e. 40 μg/ml), we detected a trend of 
infected macrophages eliciting more T-cell-produced IL-2 compared to uninfected 
macrophages and γ-irradiated-Mtb-treated macrophages (Figure 3.2). This 
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increasing trend, while not statistically significant by two-way ANOVA with Tukey 
posttest, was seen in 3 independent experiments. There was also a decreasing 
trend where γ-irradiated-Mtb-treated macrophages elicited less T-cell-produced IL-
2 compared to uninfected macrophages (Figure 3.2). However, this decreasing 
trend was seen in only 1 out of 3 independent experiments.  
 This data shows that OVA-bound beads can be phagocytosed and 
processed correctly for MHC class I presentation by macrophages treated with 
either dead Mtb or infected with live Mtb. Moreover, live Mtb infection did not inhibit 
the cross presentation of phagocytosed antigens. The limitation of this experiment 
is that we could not tell whether the phagocytosed antigens resided in the same 
phagosomes as the Mtb-containing phagosome. Therefore, this data can only tell 
us that the global, or the whole cell, ability of the infected macrophage to present 
antigen is not interfered, but it does not tell us whether the Mtb-containing 
phagosome is capable of participating in the MHC class I presentation pathway. 
Nonetheless, taking into account of the fact that polyclonal CD8+ T cells recognized 
Mtb-infected macrophages, this data supports the conclusion that Mtb-infected 
macrophages can present antigens.  
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Figure 3.2. Mtb infection does not interfere with global presentation of 
antigens. TGPMs were either uninfected, uninfected treated with γ-irradiated Mtb 
(i.e. dead bacteria), or infected with live Mtb. All samples were then treated with 
either the SIINFEKL peptide or a titration of OVA-bound magnetic beads before 
co-culturing with RF33.70 T cells. The amount of IL-2 secretion was assayed via 
ELISA.  
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TB10.4-specific CD8+ and P25 CD4+ T cells recognize macrophages 
infected with TB10.4- or Ag85b-expressing Listeria. 
We next investigated whether the location of the antigen might affect the 
presentation of TB10.4 since the MHC class I antigen presentation pathway 
primarily samples the cytosol, whereas Mtb is a classic phagosomal pathogen. 
TB10.4-specific CD8+ T cells are primed and expanded during Mtb infection, so 
the TB10.4 antigens must be cross-presented; however, whether murine, Mtb-
infected macrophages are competent to cross-present mycobacterial antigens is 
unknown. We investigated these possibilities using LLO or ActA mutant strains 
of Listeria monocytogenes engineered to express the full length TB10.4 protein, 
hereafter referred to as LLO.TB10.4 or ActA.TB10.4, respectively. Both are 
attenuated strains: the LLO.TB10.4 mutant cannot escape from the vacuole, 
while the ActA.TB10.4 mutant can escape from the vacuole but not from the cell. 
Hence, the TB10.4 protein made by the LLO.TB10.4 strain will remain trapped in 
the phagosome, but the TB10.4 protein made by the ActA.TB10.4 strain will gain 
access to the cytosol. 
TB10Rg3 T cells recognized ActA.TB10.4-infected TGPMs based on an 
increased frequency of Nur77-expressing cells (p<0.005) and the Nur77 MFI 
(p<0.005) (Figure 3.3a-c). Bafilomycin, which inhibits vacuolar acidification and 
impairs the entry of the ActA.TB10.4 strain into the cytosol, diminished the 
frequency of Nur77-expressing cells (p<0.005) and Nur77 MFI (p<0.01) (Figure 
3.3a, top, b, c). In contrast, TB10Rg3 T cells co-cultured with LLO.TB10.4-
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infected TGPMs showed no increase in the frequency of Nur77-expressing cells 
or the Nur77 MFI (Figure 3.3a bottom, d, e). If recombinant listeriolysin (rLLO), the 
protein missing from the LLO.TB10.4 strain, was added to the infected 
macrophages, an increase in the frequency of Nur77-expressing TB10Rg3 T cells 
(p<0.01) and the Nur77 MFI (p<0.01) became apparent. TB10Rg4 T cells 
responded similarly to the TB10Rg3’s, though their responses are consistently 
higher (Figure 3.3f-j). Of note, TB10Rg4 increased significantly in the frequency of 
Nur77-expressing T cells (p<0.05) even during co-culture with LLO.TB10.4-
infected TGPMs (Figure 3.3i). However, this significant increase was not seen 
when measuring the MFI of the TB10Rg4 T cell population (Figure 3.3j). 
Nonetheless, both correlates of recognition increased significantly when rLLO was 
added to the co-culture prior to adding the T cells (Figure 3.3i, j).  
We also determined whether P25 T cells recognized Ag85b-expressing 
Listeria monocytogenes using the recombinant Listeria strains ActA.Ag85b and 
LLO.Ag85b. Based on the propensity of MHC class II to present extracellular and 
vacuolar antigens, P25 cells recognized TGPMs infected with either ActA.Ag85b 
or LLO.Ag85b, based on an increase in the frequency of Nur77-expressing T cells 
and Nur77 MFI (p<0.005) (Figure 3.3k-m). These results show that 1) TGPMs can 
efficiently process the full length TB10.4 protein and present the TB10.44-11 epitope 
via MHC class I; 2) this process is more efficient when the bacteria are in the 
cytosol; and 3) TB10Rg3 T cells can efficiently recognize TB10.44-11 presented 
during a live infection. 
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Figure 3.3. TB10Rg3, TB10Rg4 and P25 T cells can recognize macrophages 
infected with Listeria monocytogenes expressing TB10.4 and Ag85b 
proteins, respectively. (a) Representative flow plots showing Nur77 induction by 
TB10Rg3 T cells after co-culture with macrophages infected with ActA.TB10 (top 
row) or LLO.TB10 (bottom row) Listeria. (b-e) Analysis of the frequency of Nur77-
expressing TB10Rg3 T cells (b, d) or normalized MFI (c, e) after co-culture with 
ActA.TB10 (b, c) or LLO.TB10 (d, e) infected macrophages. (f) Representative 
flow plots showing Nur77 induction by TB10Rg4 T cells after co-culture with 
macrophages infected with ActA.TB10 (top row) or LLO.TB10 (bottom row) 
Listeria. (g-j) Analysis of the frequency of Nur77-expressing TB10Rg4 T cells (g, i) 
or normalized MFI (h, j) after co-culture with ActA.TB10 (g, h) or LLO.TB10 (i, j) 
infected macrophages. (k) Representative flow plots showing Nur77 induction by 
P25 T cells after co-culture with macrophages infected with ActA.TB10 (top row) 
or LLO.TB10 (bottom row) Listeria. Analysis of the frequency of Nur77-
expressing P25 T cells (l) or normalized MFI (m) after co-culture with ActA.TB10- 
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or LLO.TB10-infected macrophages. Representative of at least two experiments. 
Statistical testing by one-way ANOVA with Dunnett posttest. *, p<0.05; **, p<0.01; 
***, p<0.005; ****, p<0.0001.  
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TB10.4-specific CD8+ T cells do not recognize Mtb overexpressing TB10.4. 
 Antigen abundance can affect T cell recognition, so we next tested whether 
increasing the level of TB10.4 protein expression might enhance TB10Rg3 T cell 
recognition of Mtb-infected macrophages. Since Mtb secretes esxH (TB10.4) 
together with esxG as a heterodimer [250], we developed a recombinant strain of 
H37Rv (esxGH-OE.Mtb), which overexpresses both esxG and esxH under the 
control of a tetON promoter. After tetracycline induction for 24 hours, the esxG and 
esxH mRNA expression increased multiple folds (Figure 3.4a). Prior to in vitro 
infection, we treated esxGH-OE.Mtb with or without tetracycline. The next day, 
TGPMs were infected with uninduced or tetracycline-induced esxGH-OE.Mtb. P25 
T cells produced similar amounts of IFNγ when co-cultured with macrophages 
infected with either uninduced or induced esxGH-OE.Mtb, which was expected 
since Ag85b expression should not be altered (Figure 3.4b). Despite increasing 
the production of TB10.4 by Mtb, TB10Rg3 T cells still did not recognize Mtb-
infected macrophages (Figure 3.4c). Moreover, we also assessed the ability of 
TB10Rg4 T cells to recognize TGPMs infected with esxGH-OE.Mtb. Out of 4 
experiments, 2 experiments showed no specific IFNγ production while the other 2 
experiments showed specific increase in IFNγ production even when co-cultured 
with TGPMs infected with uninduced esxGH-OE.Mtb (data not shown). Due to this 
inconsistency, it was challenging to make a formal conclusion for TB10Rg4 T cells. 
Nonetheless, the trend that TB10Rg4 T cells may produce IFNγ when co-cultured 
with Mtb-infected TGPMs hint at the importance of the increased affinity for 
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TB10.4. Although we cannot be certain that the induction of EsxGH leads to an 
increased amount of antigen delivered to the antigen processing pathway, this 
result suggests that antigen abundance is not limiting TB10.4-specific CD8+ T cell 
recognition of Mtb-infected macrophages. 
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Figure 3.4. TB10.4-specific CD8+ T cells do not recognize Mtb overexpressing 
TB10.4. (a-c) EsxG (TB10.4) and its partner EsxH were overexpressed together 
in H37Rv to determine whether increasing TB10.4 abundance would lead to 
recognition of infected macrophages (esxGH-OE.Mtb). (a) Tetracycline treatment 
of esxGH-OE.Mtb in broth culture induces esxG and esxH, but not fbpB and sigA, 
mRNA as measured by qPCR. Fold-induction was normalized to baseline (i.e., 
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uninduced). IFNγ production by (b) P25 or (c) TB10Rg3 T cells after co-culture 
with macrophages infected with uninduced or induced esxGH-OE.Mtb.  
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Macrophages cross-present antigens from non-viable Mtb to TB10.4-specific 
CD8+ T cells. 
Next, we hypothesized that Mtb may interfere with MHC class I presentation 
of mycobacterial antigens, specifically TB10.4. Therefore, we tested the ability of 
the P25 and TB10Rg3 T cell lines to recognize TGPMs cultured with γ-irradiated, 
nonviable Mtb. Activation of pattern recognition receptors such as TLR2 and TLR4 
by large amounts of dead bacteria might induce large amounts of IL-12 and IL-18, 
resulting in cytokine-driven T cell activation. Taking this concern into consideration, 
we used MHC-mismatched TGPMs as a control. We pulsed macrophages with a 
dose titration of γ-irradiated Mtb, then added TB10Rg3 or P25 T cells, and 
measured IFNγ secretion by the T cells after 72 hours. Both P25 and TB10Rg3 T 
cells produced high amounts of IFNγ when cultured with MHC-matched (i.e., H-2b) 
but not with MHC-mismatched (i.e., H-2k), TGPMs, and this response was dose 
dependent (Figure 3.5a, b). The ability of macrophages to process and present 
TB10.4 after phagocytosing γ-irradiated Mtb but not viable bacteria raises the 
possibility that live Mtb actively inhibit MHC class I presentation of TB10.4. 
 Given that cross presentation of non-viable Mtb can lead to efficient 
recognition by TB10.4-specific CD8+ T cells, we next investigated whether pre-
activating macrophages might lead to better recognition. Pre-activation of 
macrophages with IFNγ has been shown to lead to enhanced antimicrobial effects 
[251] [252] [44, 253, 254]. Thus, TGPMs were pre-treated with 25ng/ml of IFNγ 
overnight, washed, and infected with Mtb. When T cells were co-cultured from d0 
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to d3 post infection, no consistent increase in IFNγ was observed for TB10Rg3 
and TB10Rg4 T cells (data not shown). We also examined later infection time 
point, from d3 to d6 post infection. After 72 hours of co-culture, there was minimal 
amount of background IFNγ, indicating that the washing step did not leave residual 
IFNγ in the co-culture (Figure 3.5c-e). P25 T cells showed increased IFNγ 
production when the TGPMs were pretreated with IFNγ (p<0.05) (Figure 3.5c). 
TB10Rg3 T cells showed large increase in IFNγ production when the TGPMs were 
pretreated with IFNγ, however, this increase was not significant when analyzed via 
two-way ANOVA with Sidak posttest (Figure 3.5d). TB10Rg4 T cells showed 
significant, MHC class I-restricted increase when co-cultured with TGPMs 
pretreated with IFNγ (p<0.05) (Figure 3.5e).  
 We examined an additional molecule for pre-activating macrophages by 
pretreating TGPMs with IL-32. IL-32 is a human cytokine important in protecting 
the human host against Mtb [255]. Interestingly, IL-32 can also protect mice 
against Mtb infection [256]. In Mtb-infected THP-1 macrophages, IL-32 has been 
shown to lead to increased apoptosis of the infected cells [257]. We pre-treated 
TGPMs with IL-32 for 1 hour prior to infection. After co-culturing Mtb-infected, IL-
32-pretreated TGPMs with T cells, we found that TB10Rg3 did not have consistent 
increase in IFNγ production (Figure 3.5f). However, TB10Rg4 T cells exhibited 
significant, MHC class I-restricted IFNγ production, and that production was 
dependent on the dose of IL-32 used (Figure 3.5g).  
99 
 
 These results show that the non-viable Mtb (i.e. γ-irradiated Mtb) can be 
presented by TGPMs, and that presentation leads to MHC-specific recognition by 
the TB10Rg3 T cells. Moreover, pre-activating macrophages with either IFNγ or 
IL-32 led to MHC-specific recognition as well, though TB10Rg4 responded better 
than TB10Rg3 T cells. These data support the notion that live Mtb may actively 
inhibit the presentation of TB10.4.  
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Figure 3.5. Macrophages cross-present antigens from non-viable Mtb to 
TB10.4-specific CD8+ T cells. (a) P25 and (b) TB10Rg3 production of IFNγ after 
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co-culture with macrophages pulsed with titrated amounts of γ-irradiated (non-
viable) H37Rv. (c-e) TGPMs were pretreated with 25ng/ml IFNγ overnight prior to 
infection. After 72 hours of co-culture, the IFNγ produced by (c) P25, (d) TB10Rg3, 
and (e) TB10Rg4 T cells were measured. (f-g) TGPMS were pretreated with either 
100ng/ml (+) or 200ng/ml (++) IL-32 for 1 hour prior to infection. After 72 hours of 
co-culture, the IFNγ produced by (f) TB10Rg3 and (g) TB10Rg4 T cells were 
measured. Data is representative of 3 (a-b) or 2 (c-g) experiments. Statistical 
testing by one-way ANOVA with Dunnett posttest (a-b) or two-way ANOVA with 
Sidak posttest (c-g). *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.0001. φ, 
macrophages. 
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Discussion  
 
We investigated several mechanisms that might explain why TB10.4-
specific CD8+ T cells do not recognize infected macrophages. We confirmed that 
Mtb-infected macrophages only had decreased MHC I and MHC II expression 
when the macrophages were pre-activated with IFNγ. In our in vitro model, where 
the macrophages were not activated with IFNγ, we found there was no decrease 
in either MHC I or II expression, indicating that Mtb did not interfere with their 
expression levels and that the lack of recognition could not be explained by this. 
Pre-activating macrophages with either IFNγ or IL-32 led to increased MHC-
specific recognition by the TB10.4-specific CD8+ T cells, with the TB10Rg4 T cells 
having a better overall response. We also found that Mtb infection did not hinder 
the overall presentation of antigens during the OVA-coated beads studies, and this 
supports our finding that other antigens can be presented as evidenced by the 
recognition from the polyclonal CD8+ T cells. 
Another possibility is the access of the TB10.4 antigen to the MHC class I 
processing pathway. Mtb can disrupt the phagosomal membrane and translocate 
into the cytosol [258], though this action often occurs later in infection and leads to 
necrosis of the macrophage [259]. We saw no evidence of recognition even at late 
time points such as days 4-5 post infection (Fig 3). The importance of antigen 
location became apparent during the Listeria infection experiments, where infected 
macrophages presented TB10.44-11 only when the bacteria could enter the cytosol 
(i.e., ActA.TB10 but not LLO.TB10). The Listeria experiments also provided an 
103 
 
additional insight. Lindenstrom et al report that vaccination with TB10.4 (EsxH), 
which has a leucine at position 12 (i.e., IMYNYPAML), inefficiently generates 
TB10.4-specific CD8+ T cells [260]. However, vaccination with TB10.3 (EsxR), a 
related antigen that also contains the same epitope followed by a methionine (i.e., 
IMYNYPAMM), elicits TB10.4-specific CD8+ T cells. This led them to conclude 
there is a processing defect that prevents the generation of the TB10.44-11 epitope 
from the TB10.4 protein. However, they also find that TB10.4-specific CD8+ T cells 
elicited by TB10.3 vaccination recognize splenocytes pulsed with the rTB10.4 
proteins, showing that the full length TB10.4 protein can be processed and 
presented. These data indicate that the lack of vaccine-elicited TB10.4-specific 
CD8+ T cells is due to a problem with priming after vaccination instead of an 
inability to process the IMYNYPAM epitope. Moreover, our data using TB10.4 
expressed by Listeria show that TGPMs can process the full length TB10.4 protein 
and present the TB10.44-11 epitope. Therefore, we conclude that the processing of 
TB10.4 is not hindered by its amino acid sequence, and antigen location may be 
an important factor in antigen presentation. While the Listeria experiments show 
the potential importance of antigen location and raise the possibility that 
sequestration of the TB10.4 antigen in the phagosome renders it inaccessible to 
the MHC class I presentation pathway, another important variable is antigen 
abundance.  
We have previously argued that there is limited amount of TB10.4 antigen 
presentation in the lungs of infected mice, leading to extreme bias in the TCR 
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repertoire of the TB10.4-specific CD8+ T cell response and defects in the memory-
recall response in vivo [227, 231]. We considered whether low TB10.4 abundance 
could explain why Mtb-infected macrophages do not present TB10.4. To test this 
possibility, we overexpressed EsxG and EsxH (TB10.4) together but did not see 
greater T cell recognition of Mtb-infected macrophages, suggesting that 
abundance might not be the issue.  
Unexpectedly, macrophages pulsed with γ-irradiated Mtb were recognized 
by TB10.4-specific CD8+ T cells, raising the possibility that live Mtb actively inhibits 
MHC class I presentation of TB10.4. This is particularly interesting since the 
presentation of CFP-10, another ESAT-6-like protein, by human DCs to CD8+ T 
cells requires viable Mtb; DCs given heat-killed bacteria do not present CFP10 to 
T cells [216]. While these data suggest that presentation requires active secretion 
of CFP10 [261, 262], the heat-killing process could have destroyed CFP10, or 
there might not have been sufficient amounts of CFP10 available in the non-viable 
bacteria. On the other hand, Russell et al demonstrate that infection of mice with 
recombinant ovalbumin (rOVA)-expressing BCG reduces CD8+ T cell priming 
compared to when the mice are infected with rOVA-expressing Listeria 
monocytogenes; but increasing the amount of OVA being expressed corrects the 
defect [143]. This finding also suggests that live mycobacterial infection may hinder 
antigen presentation of antigens that are presumed to be in the same phagosome 
as the bacterium. Our data supports this idea. In combination with our data 
showing polyclonal CD8+ T cells recognize Mtb-infected macrophages, these data 
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suggest that it is possible that certain antigens are presented by live Mtb while 
others are actively prevented from being sampled by MHC class I. Together, the 
investigation into the mechanisms behind the lack of recognition have shown that 
there is an active inhibitory process by the Mtb that prevents efficient presentation 
of the TB10.4 protein. Future studies may focus on how exactly Mtb manipulates 
the host cell or modifies its own behavior to prevent presentation of TB10.4.  
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CHAPTER IV. DISCUSSION 
 
In 2015, TB overtook HIV to become the leading cause of death by an 
infectious disease in the world [1]. While global public health efforts have 
drastically reduced the mortality rate, the rate at which multi-drug resistant strains 
of TB are emerging is alarming. Therefore, research efforts focusing on new 
therapeutics and vaccine targets are of great significance. It is our goal that, by 
examining how the host interacts with the pathogen, we may gain a better 
understanding of the pathogenesis and identify processes that may be exploited 
against Mtb. To that end, we began our study with a fundamental question: Do 
antigen specific CD8+ and CD4+ T cells recognize Mtb-infected macrophages?  
In Chapter II, we examined this question by assessing the ability of TB10.4-
specific CD8+ T cells or antigen-specific CD4+ T cells to recognize Mtb-infected 
cells. We found that, while antigen-specific CD4+ T cells recognized Mtb-infected 
macrophages, TB10.4-specific CD8+ T cells did not. This was a particularly 
interesting result as other Mtb-specific CD8+ T cells have been found to produce 
IFNγ, upregulate activation markers and reduce bacterial burden (See Chapter I. 
Introduction). However, only two of those studies showed that recognition MHC-
restricted. This prompted us to investigate the second question: Why is there a 
lack of efficient recognition by TB10.4-specific CD8+ T cells?  
In Chapter III, we took multiple approaches to probe the mechanisms that 
could lead to poor recognition. Live Mtb infection did not hinder antigen 
presentation at a whole cell level. Nor did it inhibit MHC class I and II expression 
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in un-activated TGPMs. Interestingly, TB10.4-specific CD8+ T cells recognized 
TGPMs infected with TB10.4-expressing Listeria monocytogenes when the 
bacteria are allowed into the cytosol. The most important finding was that 
macrophages could present TB10.4 from non-viable Mtb to TB10.4-specific CD8+ 
T cells. This supports the idea that live Mtb may actively prevent the presentation 
of TB10.4 by MHC class I. 
Together, our data from these two chapters highlight the importance of 
assessing recognition as part of understanding the host-pathogen interaction. Our 
systematic approach has uncovered a difference in the recognition of Mtb-infected 
macrophages by TB10.4-specific CD8+ T cells and antigen-specific CD4+ T cells, 
raising several intriguing questions for further investigation. In the following 
discussion, I will summarize the major findings and areas for improvement from 
each chapter, raise new questions for investigation, and outline the approaches 
that might enable us to better understand how Mtb evades T cell immunity.  
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Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their 
capacity to recognize Mtb-infected cells 
Summary of results 
We investigated the ability of TB10.4-sepcific CD8+ and Ag85b-specific 
CD4+ T cells to recognize Mtb-infected cells. TB10.4 (EsxH) is a secreted protein 
important in iron and zinc acquisition, and Mtb requires it in order to survive both 
in vitro and in vivo [224, 225]. Our interest in TB10.4 comes from the finding that 
TB10.44-11-specific CD8+ T cells make up ~35-40% of total lung CD8+ T cells during 
murine infection (Figure 2.1) [226, 227]. Yet, despite eliciting large numbers of 
TB10.4-specific CD8+ T cells, a vaccine incorporating the H-2 Kb-restricted 
epitope, TB10.44-11, failed to protect mice from Mtb infection [231]. We 
hypothesized that the inability of TB10.4-specific CD8+ T cells to mediate 
protection may be due to inefficient recognition of Mtb-infected macrophages. We 
also investigated recognition by Ag85b-specific CD4 T cells. In vivo data shows 
that Ag85b-specific CD4+ T cells can recognize Mtb-infected cells early during 
infection; however, recognition decreases after infection is established [89, 144, 
184, 185, 244]. Whether these cells recognize Mtb-infected macrophages in vitro 
remains controversial.  
In our in vitro infection model, we found that TB10.4-specific CD8+ T cells 
did not recognize or reduce bacterial burden in Mtb-infected macrophages. 
Increasing the MOI, examining at different time points, or the length of the co-
culture did not lead to better recognition by the TB10Rg3 T cells. TB10Rg4 T cells, 
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which have a higher affinity to TB10.44-11 than TB10Rg3 T cells, showed some 
ability to recognize Mtb-infected macrophages based on IFNγ production. 
However, those results were not always significant or reproducible. In co-cultures 
with Mtb-infected BMDCs, TB10Rg4 T cells consistently produced IFNγ in a MHC-
restricted manner, whereas similar results from TB10Rg3 T cells were not 
reproducible. The finding that DCs present TB10.4 is not surprising as DCs are the 
primary cells found in the LN that prime the T cells [61]. The lack of recognition of 
Mtb-infected macrophages is still important since macrophages remain a dominant 
population of infected cells during established infection [235]. Under the same 
conditions where TB10Rg3 and TB10Rg4 T cells did not recognize Mtb-infected 
macrophages, P25 T cells recognized and reduced bacterial burden. Extending 
these experiments to ex vivo cells, we discovered that TB10Rg3 and TB10Rg4 did 
not proliferate when co-cultured with lung APCs from infected mice. Since Ag85b 
expression is decreased after 3 weeks post infection, we used an ESAT-6-sepcific 
CD4+ T cell line [144]. ESAT-6 is another immunodominant antigen that can help 
form pores in the phagosomes to allow Mtb to escape into the cytosol  [263]. Co-
culture of the ex vivo APCs with ESAT-6-specific CD4+ T cells showed that those 
CD4+ T cells could proliferate, which requires cognate recognition [179, 264]. We 
also wondered whether the lack of recognition by TB10.4-specific CD8+ T cells 
may indicate a global defect in which all CD8+ T cells generated during Mtb 
infection may have limited recognition ability, and this was further explored in the 
Chapter III. Interestingly, polyclonal CD8+ T cells from the lungs of infected mice 
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recognized Mtb-infected macrophages in a MHC-restricted manner, and it was the 
non-TB10.4-tetramer CD8+ T cells that recognized those macrophages. This 
important finding also illustrates that there is no global defect in antigen 
presentation or processing. Nonetheless, we could not exclude the possibility that 
there may still be decreased antigen presentation. 
 
Future directions 
 Our findings show that TB10.4-specific CD8+ T cells do not recognize Mtb-
infected macrophages while Ag85b-specific CD4 and ESAT-6-specific CD4+ T 
cells do. Before discussing the future plans, there are a few limitations to our study 
that could be addressed in the future.  
 Our findings that the TB10.4-specific CD8+ T cells have limited recognition 
of Mtb-infected macrophages is set in a specifically defined context. First, while we 
exhaustively investigated various infection and experimental parameters to detect 
recognition, our in vitro infection model cannot reflect the physiologic environment 
during chronic infection. Infected TGPMs can stay healthy for about one week after 
infection, after which the TGPMs will start to die due to increased bacterial burden 
(observations from the lab). There is evidence that suggests that CD8+ T cells are 
more effective during later stages of infection [107, 108]. Both CD4+ and CD8+ T 
cells can become exhausted during chronic infection [265], and it is possible that 
the effectiveness of CD8+ T cells is better appreciated during a setting when CD4+ 
T cells are functionally exhausted [145]. On the other hand, the infected 
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macrophages and the Mtb may change as well [266] Nonetheless, it is still 
unknown whether TB10.4-specific CD8+ T cells recognize Mtb-infected cells in late 
infection in vivo. TB10.4-specific CD8+ T cells persist after 3 months in infected 
C57BL/6 [231] or 9 months in infected BALB/c mice [226]. Whether these 
persistent TB10.4-specific CD8+ T cells may recognize during late infection is not 
easy to dissect in an in vitro model. While we attempted this by looking into co-
cultures of T cells and Mtb-infected macrophages from d3 to d6, this may not 
represent a real late infection. Future directions should examine whether the 
TB10.4-specific CD8+ T cells in the lungs of infected mice in late infection might 
recognize Mtb-infected macrophages. To examine the antigen recognition during 
late infection or in an in vivo setting, we can use a similar approach as taken by 
Bold et al [144]. Briefly, we can adoptively transfer TB10.4-specific CD8+ T cells 
expressing the congenic marker CD45.1 into Mtb-infected mice and then isolate 
these cells during late infection and assess their production of IFNγ ex vivo without 
stimulation. IFNγ production can be an indicator that these T cells may be 
recognizing TB10.4 in the lung environment.  
 Our study of antigen-specific CD8+ and CD4+ T cell recognition takes place 
in only one host genotype, C57BL/6. The C57BL/6 and BALB/c mice are known to 
be more resistant to Mtb compared to other mouse strains [267], and the TB10.4-
specific CD8+ T cell response is dominant in both C57BL/6 and BALB/c mice [226, 
227]. Smith et al expanded on this concept by examining 10 different inbred mouse 
strains and identified new susceptible and resistant mouse genotypes [268]. It will 
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be interesting to see the frequency of TB10.4-specific CD8+ T cells in the lungs of 
these newly defined resistant and susceptible mice. This will be met with the 
challenge of having to map which epitopes the T cells respond to in the different 
host genotypes. One could also expand that search to cover other major Mtb 
antigens. The end result will illustrate whether the generation of TB10.4 or the lack 
therefore may or may not correlate with susceptibility to Mtb. 
 For ex vivo CD4+ and CD8+ T cell studies, we are limited by our current set 
of reagents to analyze TB10.4-specific responses. The isolation of TB10.4-specific 
CD8+ T cells using tetramers may inadvertently have activated those T cells, 
making it difficult to assess whether they can recognize Mtb-infected macrophages 
during co-cultures due to high background activation. To circumvent this, we can 
try to use the Nur77-GFP mouse developed by Moran et al [233]. Specifically, 
Nur77 is a transcription factor upregulated after TCR activation, and the Nur77-
GFP mouse will have the GFP expression after TCR activation. We can infect the 
Nur77-GFP mice, which are on a C57BL/6 background, and, at different times after 
infection, we can isolate the lung CD8+ T cells and co-culture them with Mtb-
infected macrophages. Then, we can use tetramer staining on the GFP+ and GFP- 
population to confirm whether the activated T cells are TB10.4-specific or not. This 
would enhance our finding that polyclonal, non-TB10.4-tetramer-positive T cells 
recognize Mtb-infected macrophages.  
 We considered the possibility of using BMDMs in our study to expand the 
applicability of our findings. However, preliminary studies showed that the BMDMs 
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triggered high background and non-specific recognition (i.e. high signal from the 
MHC mismatched BMDMs). This prompted us to use the ex vivo APCs as a way 
to illustrate the recognition capabilities in the presence of a heterogeneous 
population of lung APCs. While the lung APCs isolated using MHC II microbeads 
do contain dendritic cells and macrophages, we may need to isolate and enrich 
specific populations such as alveolar macrophages for a more specific 
investigation. Moreover, our lab has found that aerosol infection of mice does not 
lead to a high percentage of lung APCs being actually infected. While this finding 
is consistent with natural infection where the initial infection burden is not very high, 
it raises the question of how many infected cells are present in the co-culture. A 
more effective approach may be to do a high dose aerosol, or IV, or intratracheal 
infection with a fluorescent-protein-expressing-Mtb, such as YFP-Mtb. We can 
subsequently isolate the lung cells, sort only the infected cells based on 
fluorescence, and then plate those cells and see if TB10-specific CD8+ T cells 
might recognize them better. This approach does also investigate the question of 
antigen abundance, which is explained more in detail in the next section. 
 While the above approaches help to improve the study, there are exciting 
future directions that we should pursue as well. Despite showing that TB10.4-
specific CD8+ T cells do not recognize Mtb-infected cells, there is overwhelming 
evidence that these CD8+ T cells persist during infection. Presumably, there must 
be a population of cells that are recognized that lead to the persistence of those 
cells. We return to the idea that there is a detour pathway in antigen presentation. 
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Through the works of Winau et al and Schaible et al, we now know that DCs can 
pick up apoptotic vesicles containing live Mtb or pieces of bacteria and prime naïve 
T cells in the LN [212, 240, 269]. While they describe this scenario in the context 
of priming, it is possible that such a process may occur in the infected lung. One 
can imagine the scenario where an uninfected bystander macrophage 
phagocytoses a dying, Mtb-infected macrophage, and, through efferocytosis, 
eliminate the bacterium inside. However, during that process, peptides can be 
generated from the dead bacterium and its proteins. These can then be presented 
to the surrounding T cells. This activation will lead to MHC-restricted or TCR-
dependent recognition; however, the end result is the recognition of an uninfected 
cell rather than an infected cell. The persistence of the T cell response without 
focusing on the infected cells could lead to inflammation without necessarily 
promoting protecting. To test whether the detour pathway may lead to better 
recognition, we can first infect MHC mismatched macrophages, induce apoptosis 
via chemical agents or UV light, and then add uninfected, MHC matched 
macrophages. If co-culture with T cells lead to TB10.4-specific CD8+ T cell 
recognition, then we can conclude that cross presentation of apoptotic vesicles 
can lead to activation. This also supports the notion that TB10.4 in the presence 
of dead bacteria can be presented. In this experiment, we must be careful to 
ensure that the uninfected bystander macrophages do not become infected by Mtb 
that have escaped from dying cells.  
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 Earlier, we alluded to the fact that our T cells represent 2 TCRs that 
recognize TB10.44-11. The generation of these TCRs comes from isolating TB10.4-
specific CD8+ T cells from infected, vα2var mice [227]. To broaden the scope of 
our study, we can generate more TB10.4-specific CD8+ T cells and try to 
investigate whether other TCRs may also have difficulty in recognizing Mtb-
infected macrophages. Indeed, others in the lab have generated several new 
TB10.4-specific T cell lines with TCRs isolated from infection of C57BL/6 mice. 
Data from those experiments have so far been negative, in the sense that TB10.4-
specific CD8+ T cells do not recognize Mtb-infected macrophages (Rujapak 
Sutiwisesak). 
 Another future direction is to focus on the T cells that recognize Mtb-infected 
macrophages and, consequently, the antigens being presented. The polyclonal 
CD8+ T cells from infected mice recognized Mtb-infected macrophages, but their 
IFNγ production response was relatively small compared to that of the CD4+ T 
cells. While this could be due to an inherent capacity of CD4+ T cells to produce 
more IFNγ than CD8+ T cells [76, 270], it also suggests that the population of CD8+ 
T cells recognizing Mtb-infected macrophages is small. We can quantify the 
frequency of the CD8+ T cells recognizing Mtb-infected macrophages. Efforts are 
currently underway in the lab using polyclonal CD8+ T cells from infected mice to 
co-culture with Mtb-infected macrophages and calculating the frequency of IFNγ 
produced spots in an ELISPOT assay (Yash Patankar). Correlating the frequency 
of CD8+ T cell responding to Mtb-infected macrophages in a MHC-restricted 
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manner will, predictably, further highlight the small frequency of responding CD8+ 
T cells, which dwarf in comparison to TB10.4-specific CD8+ T cells.    
 Next, we can try to identify the antigen specificity of the responding CD8+ T 
cells. We can isolate CD8+ T cells from the lungs of Nur77-GFP infected mice, use 
GFP to sort out the activated polyclonal CD8+ T cells after co-culture with Mtb-
infected macrophages. We can attempt to culture them in vitro with anti-CD3 and 
CD28 antibodies and supportive cytokines such as IL-2 and IL-7. Finally, we will 
screen a peptide library consisting Mtb antigen epitopes using an IFNγ ELISA or 
ELISPOT as readout. This screening method, though tedious, has been used 
before in identifying epitopes recognized by T cells from human and murine studies 
[114, 228]. The result will illustrate the epitopes recognized by the polyclonal CD8+ 
T cells and indicate a pool of peptides that may be presented during infection. 
Identifying which epitopes are presented and recognized during infection will allow 
for new vaccine targets. 
In our studies, we found that Ag85b-specific and ESAT-6-specific CD4+ T 
cells recognized Mtb-infected macrophages and ex vivo APCs. As highlighted in 
Chapter I and Chapter II Discussion, there are studies that support Ag85b-specific 
CD4+ T cells recognizing Mtb-infected macrophages and studies that challenge 
that idea. An important finding that supports antigen recognition is that the 
reduction of bacterial burden requires cognate recognition via cell-to-cell contact 
[170]. Given that Ag85b-specific CD4+ T cells reduced bacterial burden in a MHC-
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restricted manner, we believe that the Ag85b-specific CD4+ T cells do recognize 
Mtb-infected macrophages.   
Nonetheless, we cannot exclude the possibility that the P25 T cells in our in 
vitro infection are recognizing bystander macrophages that have picked up Ag85b 
or vesicles through the detour pathway. Uninfected APCs can acquire Mtb 
antigens through the engulfment of apoptotic cells, necrotic debris, exosomes or 
uptake of exported antigens, and T cells may recognize these uninfected APCs 
but miss the infected cells [212, 240]. To fully investigate this, we can take 
advantage of live cell imaging. Unlike other experimental setups, live cell time 
lapse imaging allows direct observation of interactions between T cells and Mtb-
infected cells. Macrophages infected with fluorescent bacteria can be visualized 
under the microscope, and the length of time when the T cells are interacting with 
those macrophages can be recorded. We can draw a baseline interaction time 
based on the T cells interaction with uninfected macrophages and compare that to 
the times with the infected macrophages. We have already set up preliminary 
experiments and are currently analyzing this data. Direct observation and 
quantification will allow a much better assessment of whether the detour pathway 
may be causing P25 T cell recognition, or whether the recognition is indeed of Mtb-
infected cells. Moreover, we can extend this method to also assess ex vivo CD4+ 
and CD8+ T cells to also ascertain that the recognition that we have observed 
comes from recognition of infected cells as well.  
119 
 
In this chapter, we investigated the recognition ability of CD8+ and CD4+ T 
cells specific to immunodominant antigens. Our findings show that 
immunodominant antigens may generate CD8+ T cells that do not recognize Mtb-
infected macrophages, implicating the antigen as a potential decoy antigen. Rather 
than discounting the TB10.4-specific CD8+ T cells as unimportant, we can 
approach this from an alternative angle. TB10.4-specific CD8+ T cells exist in great 
numbers in both human and murine models. The challenge is that they do not 
recognize the infected targets. If we can figure out how to enable these T cells to 
recognize Mtb-infected macrophages, then we already have a large T cell 
response that can eliminate the bacteria. To get us closer to that reality, we must 
first understand the mechanism by which the TB10.4-specific CD8+ T cells do not 
recognize Mtb-infected macrophages.  
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Investigating mechanisms of non-recognition by TB10.4-specific CD8+ T 
cells 
Summary of results 
 In this chapter, we aimed to investigate the mechanisms that may explain 
why there was a lack of recognition of Mtb-infected macrophages by the TB10.4-
specific CD8+ T cells. As mentioned in Chapter I and Chapter III, there are many 
mechanisms by which Mtb can escape or evade T cell immunity. We approached 
this investigation by focusing on the APC first, then the T cells, and, finally, the 
bacterium itself. This approach allowed us to eliminate quality control issues and 
arrive at the conclusion that there is an active process that inhibits the presentation 
of TB10.4-specifically.  
 In investigating the TGPMs, we found that Mtb did not interfere with MHC I 
or II expression in the infected macrophages. Mtb did inhibit MHC I and II 
expression during later days of infection if the TGPMs were pretreated with IFNγ, 
and this is consistent with published studies [148, 149]. We also found that Mtb did 
not interfere with the global presentation of antigens when the OVA-coated beads 
were added to the Mtb-infected macrophages. Indeed, SIINFEKL-specific 
hybridoma, RF33.70, T cells made IL-2 when the OVA-coated beads were co-
cultured with MTb-infected macrophages.  
 We next investigated whether TB10.4 CD8+ T cells could recognize TB10.4 
expressing-Listeria monocytogenes. We found that, if the Listeria were allowed to 
escape into the cytosol, then the TB10.4-specific CD8+ T cells recognized them. 
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This experiment confirmed that the TB10.4-specific CD8+ T cells could recognize 
the TB10.44-11 epitope generated during infection. Prior to this experiment, our 
positive control that both TB10Rg3 and TB10Rg4 T cells recognized TB10.44-11 
came from peptide pulsed studies. Although TB10Rg4 recognized Mtb-infected 
BMDCs, we had no positive data on the recognition of macrophages. Second, this 
study also confirmed that the macrophages were capable of processing the full 
length TB10.4 protein into the minimally recognized epitope for presentation. As 
indicated during the previous discussion, studies have argued that  the processing 
of the TB10.4 epitope may be inefficient and leads to suboptimal activation [260]. 
However, our findings show that the macrophages can process the whole protein. 
Third, this experiment showed that the location of the bacteria might be important 
given that the recognition of the TB10.4 expressing Listeria was only achieved 
when the bacteria could escape from the phagosome into the cytosol. Several 
studies have shown that Mtb can form pores on the phagosomal membranes and 
may translocate into the cytosol after infection [258, 263, 271, 272]. However, that 
translocation often indicates imminent cell necrosis, which disrupts antigen 
presentation [258, 259, 273, 274].  
Knowing that the TB10.4-sepcific CD8+ T cells could recognize TB10.4 
during an infection, we next investigated whether there was a process by the Mtb 
bacterium that is inhibiting presentation. As mentioned above, we have previously 
argued that there is limited amount of TB10.4 antigen presentation in the lungs of 
infected mice, leading to extreme bias in the TCR repertoire of the TB10.4-specific 
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CD8+ T cell response and defects in the memory-recall response in vivo [227, 231]. 
In the context of learning that Ag85b can be downregulated during infection, we 
wondered whether antigen abundance of TB10.4 might be an issue. Using a 
esxGH-over-expression strain of Mtb (esxGH-OE.Mtb), we found that there was 
no increased recognition by the TB10.4-specific CD8+ T cells, suggesting that 
antigen abundance may not be the issue that prevents efficient recognition.  
Finally, we investigated whether there was an active process of inhibition of 
TB10.4 presentation. It is important to keep in mind that we have shown that Mtb 
does not interfere with the global antigen presentation of the infected cell (Figure 
3.2), and Mtb-infected macrophages present antigens other than TB10.4 during 
infection (Figure 2.7). We found that TB10.4-specific CD8+ T cells recognized 
macrophages pulsed with y-irradiated Mtb. Using IFNγ and IL-32 to pre-activate 
the macrophages, we found TB10.4-specific CD8+ T cells, especially TB10Rg4, 
could efficiently recognize these pre-activated, Mtb-infected macrophages.  These 
results show that pulsing with non-viable Mtb or pre-activation of macrophages led 
to better presentation of TB10.4. The non-viable Mtb experiment also indicates an 
active process by live Mtb that results in the prevention of TB10.4 presentation. 
However, it remains unknown exactly how that process works.  
 
Future directions 
There are a few improvements that we can make to further our investigation. 
First, the OVA-coated beads experiment only assessed the antigen presentation 
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of the entire cell during Mtb infection. It was unlikely that the OVA-coated beads 
were in the same phagosome as the Mtb bacterium. Thus, this study only 
addressed whether Mtb infection may limit the antigen presentation ability of the 
whole cell, not just the phagosome that the Mtb is in. To address the question of 
whether Mtb-containing phagosome may be inhibited in their presentation of 
antigens, we need an alternative approach. Since Mtb-infected macrophages 
presented antigens to polyclonal CD8 T cells, we can assume that the Mtb 
containing phagosome is not inhibited from antigen presentation. Interestingly, 
Grotzke et al show that Mtb containing phagosomes from human DCs have MHC 
class I molecules and TAP, leading to the conclusion that those phagosomes are 
capable of antigen presentation [207]. Less is known about whether Mtb 
phagosomes in murine models also can present antigens. One way to address this 
question is to assess the presentation of a MHC class I antigen localized to the 
same phagosome as Mtb during Mtb infection. Using a Tet-inducible, SIINFEKL-
expressing Mtb strain, we have preliminary data showing inefficient recognition of 
the SIINFEKL peptide by the RF33.70 T cells. However, more work needs to be 
done to validate that the optimal induction of SIINFEKL is achieved (data not 
shown).  
The limitation with the Listeria studies is that 1) the TB10.4 is expressed via 
a plasmid, meaning that the protein most likely is not secreted by the bacterium, 
and 2) the expression plasmid does not express EsxG, which partners with TB10.4 
(EsxH) to form a heterodimer. It is likely that the TB10.4 protein is not functional 
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during Listeria infection. Studies have shown that TB10.4 may be involved in 
impairing the ESCRT pathway [189, 275] and in the inhibition of presentation to 
Ag85b-specific CD4+ T cells. However, we found that Mtb-infected macrophages 
presented to P25 T cells and polyclonal CD4+ T cells, and thus, we do not fully 
support the idea that TB10.4 may be detrimental to antigen presentation to CD4+ 
T cells. Differences between the studies include 1) our long-term co-culture vs. 
their short-term co-culture, and 2) our use of TGPMs and ex vivo APCs vs. their 
use of BMDMs. Furthermore, they find that CD4+ T cells mediated better bacterial 
reduction when co-cultured with BMDMs infected with a mutant strain of Mtb 
lacking TB10.4 (ΔesxH.Mtb) [189]. However, while the WT Mtb grew intracellularly 
in the samples without T cells, the mutant strain did not grow at all. This raises the 
question about the health of the mutant strain and suggests that the macrophages 
were already restricting bacterial growth. The enhanced bacterial burden control 
from the T cells may have been partially helped by the enhanced killing by innate 
macrophage antimicrobial mechanisms. Our studies with the OVA-coated beads, 
polyclonal CD8+ and CD4+ T cells from infected mice, along with Ag85b-specific 
and ESAT-6-specific T cell recognition all indicate that TB10.4 is not interfering 
with antigen presentation. However, in order to rule this out definitively, it will be 
important to obtain the ΔesxH.Mtb and see if we get even better recognition from 
P25 T cells when TB10.4 is not present.  
The Listeria studies also show that the location of the antigen and bacterium 
may be important. The interest in allowing Mtb to access the cytosol as a way to 
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increase T cell response was piqued by the finding that a BCG vaccine that 
expresses listeriolysin has increased efficacy [276]. We have attempted to elicit 
phagosomal escape using several methods. We have tried to add recombinant 
listeriolysin to the Mtb-infected macrophage culture prior to adding T cells (data 
not shown). However, this did not yield promising results for two potential reasons: 
1) listeriolysin requires a pH of below 5 to work, whereas Mtb phagosomes usually 
are in the pH > 5.5 [125, 126]; 2) addition of listeriolysin may not deliver the 
listeriolysin to the Mtb containing phagosome. We also tried using perfringolysin, 
the toxin secreted by Clostridium perfringens bacterium that forms pores in lipid 
membranes [277]. Interestingly, a perfringolysin-expressing-BCG strain (AFRO-1) 
that over-expresses Ag85A, Ag85B and TB10.4 also showed increased efficacy in 
protecting mice against TB [278]. However, in our hands, AFRO-1 infection did not 
lead to increased recognition by the TB10.4-specific CD8 T cells (data not shown). 
We found a lot of cell death during the co-culture after infection, and it is possible 
that the pore forming abilities of perfringolysin may have lysed not only the 
phagosomes but also the plasma membranes of the infected macrophages. 
Moreover, the TB10.4 may not have been expressed, which the authors admitted 
that they could not detect TB10.4 via Western blotting [278].  
While we investigated the role of antigen abundance during Mtb infection, 
we have not ruled out definitively that enough TB10.4 was produced during 
infection. To assess this, we need to probe for antigen abundance during Mtb 
infection. We have tried to quantify the amount of TB10.4 produced during infection 
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by doing Western blotting on cell lysates from Mtb-infected macrophages. 
However, we have not been able to consistently detect the protein (data not 
shown). This may be partially due to the commercial polyclonal antibody that has 
not been validated. Our next approach is to use mass spectrometry to quantify the 
amount of protein present. Furthermore, we should also assess the amount of 
TB10.4 present during in vivo infection. We can use a similar approach as Bold et 
al have done by examining the mRNA expression levels of TB10.4 at different time 
points after aerosol infection of mice [144]. We can correlate the mRNA expression 
levels with the tetramer positive frequency of CD8+ T cells to see if the sustained 
tetramer positive population corresponds to a sustained level of TB10.4 
production.  
We can also improve upon experiments concerning macrophages cross 
presenting antigens from non-viable bacteria and pre-activated, Mtb-infected 
macrophages. We used IFNγ and IL-32 to pre-activate the macrophages. While 
the results hold promise, we need to ensure that the effects we are seeing are due 
to enhanced killing versus the generation of non-viable bacteria. We can do 
parallel CFU assays to assess whether IFNγ and IL-32 pretreated macrophages 
do restrict bacterial burden better after infection. To fully appreciate the effects of 
killing, and not just restricting bacterial growth, we can use a longer infection 
course. After infection, we will rest the macrophages from d0 to d3 to allow 
intracellular bacterial to grow. Then, on d3, we add IFNγ, IL-32, or antibiotics such 
as isoniazid (INH) and assess whether the addition may lead to decrease in 
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bacterial burden. If it does, then on d5, we can add T cells for 24-72 hours to see 
if there is any recognition. The important parameter is to make sure to let the Mtb 
grow first and then reduce the bacterial burden, leading to an accumulation of dead 
bacteria that may be presented to the T cells.  
The above approaches will enhance existing findings. However, two 
questions remain: 1) what active process is preventing the presentation of TB10.4? 
2) what is sustaining the high frequency of TB10.4-specific CD8 T cells through 
chronic infection?  
To probe the process that actively inhibits antigen presentation of TB10.4, 
we can use a screening approach. We infect two groups of RAG-1-/- or TCRα-/- 
mice, one as is and the other one with adoptively transferred TB10.4-CD8+ T cells. 
We infect these mice with a transposon insertion library of Mtb mutants [225, 279, 
280]. After 4 weeks, we can plate the resulting lung homogenates, recover the 
bacterial DNA and sequence them. If there are mutants in the library that can be 
recognized by TB10.4-specific CD8+ T cells, then we should detect their absence 
in the mice that received T cells. We can potentially identify new genes that play a 
role in inhibition of antigen presentation. Of course, this approach may return gene 
candidates that we already know. However, the data will still be useful as we can 
define new mechanisms by which known genes are inhibiting the presentation of 
one specific antigen.  
Alternatively, we can examine cases where TB10.4-specific CD8+ T cells 
are not present. The clinical isolate 667 has a natural polymorphism that changes 
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an alanine to a threonine in the TB10.44-11 epitope [281], and efforts in our lab have 
identified that infection with the clinical isolate 667 does not generate TB10.4-
specific CD8+ T cells during murine infection (Rujapak Sutiwisesak). It will be 
important to assess the virulence of the bacterium, and, if there is a decreased 
virulence, whether that virulence is due to the absence of TB10.4-specific CD8+ T 
cells. We can also attempt to identify other Mtb antigens that may arise as 
immunodominant in the absence of a TB10.4 response, and we can measure the 
frequency of polyclonal CD8+ T cells that recognize Mtb-infected cells to see if 
there is an enrichment of that population. This study is critical in confirming the 
theory that TB10.4 is a decoy antigen. 
The sustained frequency of TB10.4-specific CD8+ T cells during murine 
infection is of great interest because it suggests there must be ongoing recognition. 
To answer this question, we need to accomplish 2 objectives. First, we need to 
identify the cells that are presenting TB10.4 during infection. Second, we need to 
ascertain whether these TB10.4-presenting cells contain live Mtb or apoptotic 
vesicles from Mtb-infected cells. To address the first question, we will use TCR 
tetramers. Whereas MHC-peptide tetramers are useful for identifying and 
quantifying the frequency of epitope specific T cell populations, TCR tetramers 
identify the frequency of antigen presenting cells that have epitopes that bind to 
TCRs [282]. Previous work has shown that engineering Mtb antigen-specific CD4+ 
TCR tetramer is possible and can be used to detect APCs in human peripheral 
blood that present Mtb antigens [283]. We can engineer TCR tetramers that are 
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specific to the TB10.44-11 epitope and use them to screen lung cells isolated from 
Mtb-infected mice. The mice will be infected with a live-dead strain of Mtb, which 
expresses mCherry constitutively and expresses GFP when induced with 
tetracycline [46]. Those that bind to the TCR tetramers can then be stained for 
various myeloid markers to identify whether they are DCs, alveolar macrophages, 
recruited monocytes, or another subset of APCs. Furthermore, to answer the 
second question about whether the APCs contain live or dead Mtb, we can use 
flow cytometry to assess whether the TCR tetramer positive APCs also contain live 
Mtb, which should still express GFP. If the TCR tetramer positive APCs contain 
dead Mtb or no detectable Mtb, then we can conclude that the sustained CD8+ T 
cell population comes from the presentation of non-viable Mtb via the above-
mentioned detour pathway. If this detour pathway is indeed what drives the 
maintenance of the TB10.4-specific CD8+ T cells, then we can confirm that TB10.4 
is a decoy antigen.  
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Concluding remarks 
The TB10.44-11 epitope has been extensively used to characterize CD8+ T 
cell responses in the mouse model of TB, and TB10.4-specific CD8+ T cell 
responses have also been characterized in people with tuberculosis [227, 229, 
231, 260, 284-286]. The finding that TB10.4-specific CD8+ T cells do not recognize 
infected macrophages was unexpected, particularly since TB10.4-specific CD8+ T 
cells persist in the lungs of infected mice and become more dominant with time 
[226, 227]. The data presented in this thesis help to define a set of questions that 
warrant further investigation. Briefly, the main questions are:  
1. Do TB10.4-specific CD8+ T cells exist in other diverse host genotypes? Do they 
correlate with susceptibility to TB? Do they recognize Mtb-infected cells? 
2. What are the antigens that infected cells present to the small group of 
polyclonal CD8+ T cells that recognize infected macrophages?  
3. What is the expression level of TB10.4 and does it change throughout in vivo 
infection? 
4. What sustains the high frequency of TB10.4-specific CD8+ T cells during 
murine infection? Is it the detour pathway? 
5. What bacterial genes may contribute to the inhibition of TB10.4 presentation in 
infected cells? 
The various approaches that we can take to answer these questions are 
outlined in the above discussion sections. Answering these questions will not only 
confirm whether TB10.4 is a decoy antigen or not but also inform future vaccine 
designs. 
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In retrospect, our findings may partially explain why eliciting TB10.4-specific 
CD8+ T cells by vaccination fails to protect mice against Mtb infection [231, 260]. 
While vaccination with immunodominant antigens recognized by CD4+ T cells 
(e.g., Ag85b, ESAT-6) induce moderate protection [287, 288], we must consider 
the possibility that these antigens may not be the best stimulators of protective 
immunity. Ag85b-specific CD4+ T cells have variable efficacy, in large part due to 
its reduced expression by the bacterium as early as 3 weeks after infection [144, 
145]. However, by their nature, the recruitment of memory T cell responses specific 
for immunodominant antigens is only incrementally faster than the primary T cell 
response [183, 231]. Thus, a crucial question for vaccine development is whether 
other Mtb antigens resemble TB10.4, in that they elicit T cell responses that fail to 
recognize infected macrophages. We did detect polyclonal CD8+ T cells that 
recognized Mtb-infected macrophages, corroborating a previous study showing 
that polyclonal CD8+ T cells from infected mice can lyse Mtb-infected cells [113]. 
These data indicate that there are antigens presented by Mtb-infected cells, even 
if those antigens may be subdominant compared to TB10.4. Thus, future vaccine 
developments will benefit by identifying antigen targets based on their ability of 
being presented rather than only their immunogenicity. 
Priming of TB10.4-specific CD8+ T cells occurs early after Mtb infection in 
the lung draining lymph node (LN) [138, 231]. Yet it is unknown whether priming 
of naïve T cells occurs via Mtb-infected DCs, or by uninfected DCs that acquire 
antigen through uptake of apoptotic blebs containing Mtb proteins [212, 240], or by 
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the transfer of antigen from cell to cell [242]. Being primed by an uninfected cell 
can have detrimental consequences if the infected cell presents a different 
repertoire of Mtb antigens. Considering our findings, we propose that TB10.4 is a 
decoy antigen: TB10.4-specific CD8+ T cells expand in the LN during priming, 
accumulate in the lungs, but ineffectively recognize Mtb-infected macrophages. 
This raises the hypothesis that not all immune responses elicited by Mtb provide 
benefits to the host. Interestingly, Mtb genes encoding epitopes recognized by T 
cells are more highly conserved than other DNA elements, implying that T cell 
recognition of these Mtb epitopes may provide a survival advantage to the 
bacterium [12, 13]. For example, T cell dependent inflammation may benefit Mtb 
by promoting transmission. Even though TB10.4 is more variable than most other 
antigens, our results support these genetic data [12, 13]. Thus, Mtb focuses the 
CD8+ T cell response on the decoy antigen TB10.4 and distracts the immune 
response from other antigens that might be targets of protective immunity, 
successfully evading T cell immunity and enabling it to establish itself as persistent 
infection. 
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CHAPTER V. METHODS AND MATERIALS 
Ethics Statement 
Studies involving animals were conducted following relevant guidelines and 
regulations, and the studies were approved by the Institutional Animal Care and 
Use Committee at the University of Massachusetts Medical School (Animal 
Welfare A3306-01), using the recommendations from the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health and the Office of 
Laboratory Animal Welfare.  
 
Mice 
C57BL/6J, RAG-1-/- (B6.129S7-Rag1tm1Mom), B10 (C57BL/10J), B10.BR 
(B10.BR-H2k2 H2-T18a/SgSnJJrep), P25 (C57BL/6-Tg(H-2Kb-
Tcrα,Tcrβ)P25Ktk/J) [64, 232], mice were obtained from Jackson Laboratories (Bar 
Harbor, ME). C57BL/6J and B10 mice were used for isolating MHC-matched 
TGPMs while B10.BR mice were used for isolating MHC-mismatched TGPMs. 
C57BL/6 Kb-/-Db-/- (MHC I-/-) mice were a generous gift from Dr. Kenneth Rock 
(University of Massachusetts Medical School, MA). C7 TCR transgenic mice were 
a generous gift from Dr. Eric Pamer (Memorial Sloan Kettering Cancer Center, 
NY)[239].  
 
134 
 
Thioglycolate-elicited peritoneal macrophages 
 Thioglycolate-elicited peritoneal macrophages were obtained 4-5 days after 
intra-peritoneal injection of mice with 3% thioglycolate solution, as described [55]. 
1105 macrophages were plated per well. Macrophages were maintained in culture 
with RPMI 1640 media (Invitrogen Life Technologies, ThermoFisher, Waltham, 
MA) supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine 
(all from Invitrogen Life Technologies) and 10% heat-inactivated fetal bovine 
serum (HyClone, GE Healthcare Life Sciences, Pittsburgh, PA), referred hereafter 
as supplemented complete media. 
 
Bone marrow-derived dendritic cells 
Bone marrow-derived dendritic cells were prepared as previously described 
[289]. Briefly, bone marrow cells isolated from C57BL/6 were cultured in vitro with 
complete RPMI1640 and 10ng/mL granulocyte-macrophage colony stimulating 
factor (GM-CSF) (PeproTech, Rocky Hill, NJ) for 8 days before being harvested, 
counted and plated for experiments. For infection, BMDCs were infected at MOI 
10 for 2 hours, and the wells were washed extensively after infection to get rid of 
extracellular bacteria. 
 
Generation of CD8+ and CD4+ T cell lines 
Retrogenic mice expressing TB10Rg3 TCR specific for the TB10.44-11 
epitope were generated as previously described [227]. The TB10Rg3 CD8+ T cells 
135 
 
were isolated from these mice, stimulated in vitro with irradiated splenocytes 
pulsed with the peptide TB10.44-11 in complete media containing IL-2. P25 or C7 
CD4+ T cells were isolated from transgenic P25 or C7 mice, respectively [232, 
239]. The P25 and C7 cells were stimulated in vitro with irradiated splenocytes 
pulsed with the Ag85b241-256 peptide or the ESAT-61-15, respectively, in complete 
media containing IL-2 and anti-IL-4. After the initial stimulation, these T cells were 
split every two days for 3-4 divisions and rested for two to three weeks. After the 
initial stimulation, the cells were cultured in complete media containing IL-2 and IL-
7. 
 
Peptides 
The following synthetic peptide epitopes were used as antigens: TB10.44-11 
(IMYNYPAM); Ag85b241-256 (QDAYNAAGGHNAVFN); and ESAT-61-15 
(MTEQQWNFAGIEAAA). We also generated a negative control peptide predicted 
to not bind to H-2 Kb:  IMANAPAM. The peptides were obtained from New England 
Peptides (Gardner, MA).  
As positive controls assessing the function of macrophages to present 
antigen, uninfected macrophages and, in certain experiments, infected 
macrophages were pulsed with the peptides of interest. We pulsed macrophages 
by incubating 10uM of the peptides of interest with the macrophages in 
supplemented complete RPMI 1640 media for 1 hour. After incubation, the cells 
were washed 3 to 5 times with fresh supplemented complete RPMI 1640 media. 
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The cells were then resuspended in supplemented complete RPMI 1640 media for 
experiments.    
 
In vitro Mtb infection 
H37Rv was grown as previously described [55]. Bacteria was grown to an 
OD600 of 0.6 – 1.0, washed in RPMI, opsonized with TB coat (RPMI 1640, 1% heat-
inactivated FBS, 2% human serum, 0.05% Tween-80), washed again and filtered 
through a 5-micron filter to remove bacterial clumps. The bacteria were counted 
using a Petroff-Hausser chamber. Infection was performed as previously 
described [55]. The final multiplicity of infection (MOI), based on plating CFU, was 
0.2-0.8 for all experiments. For CFU-based, bacterial growth inhibition assays, T 
cells were added at a ratio of 5 T cells to each macrophage. Four replicate wells 
were used for each condition. Cell cultures were lysed by adding 1/10th volume of 
with 10% Triton X-100 in PBS (final concentration of 1%), and CFUs were 
determined by plating in serial dilutions of the lysates on Middlebrook 7H10 plates. 
CFUs were enumerated after culture for 21 days at 37°C and 5% CO2.  
 
In vivo aerosol Mtb infection and lung cell isolation 
Aerosol infection of mice was done with the Erdman strain of Mtb using a 
Glas-Col aerosol-generation device. A bacterial aliquot was thawed, sonicated for 
1 minute and then diluted in 0.9% NaCl-0.02% Tween-80 to 5 ml. The number of 
Mtb deposited in the lungs was determined for each experiment, by plating 
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undiluted lung homogenate from a subset of the infected mice within 24 hours of 
infection.  The inoculum varied between 37-120 CFU. For the ex vivo APC 
experiments, lung cells were isolated from Erdman-infected, RAG-1-/- mice, 4-
weeks post-infection, and the APCs were enriched by positive selection using anti-
MHC class II+ microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and the 
Miltenyi AutoMACS. On average, the isolated cells were 89% CD11c+ or 
CD11c+CD11b+. The APCs were counted on a hemocytometer and plated at 1x105 
per well in supplemented complete RPMI 1640 media.  
For the ex vivo CD4+ and CD8+ T cell experiments, single cell suspensions 
were isolated from the lungs of infected C57BL/6 mice, 6 to 8 weeks post-infection, 
as described [183]. Polyclonal CD4+ and CD8+ T cells were enriched by positive 
selection using Mouse CD4+ and Mouse CD8+ T cell isolation kits, respectively 
(Miltenyi Biotec). After enrichment, average purity for polyclonal CD4+ and CD8+ T 
cells were 93% and 95%, respectively. For experiments investigating TB10.44-11-
tetramer positive cells and polyclonal, non-TB10.4-specific, CD8+ T cells, the 
following isolation was done. Single cell suspensions from the lungs of infected 
mice were incubated with APC-conjugated, TB10.4-4-11-loaded, H-2b tetramers 
from the National Institute of Health Tetramer Core Facility (Emory University 
Vaccine Center, Atlanta, GA). Tetramer positive CD8+ T cells were then selected 
via the AutoMACS separator by anti-APC microbeads (Miltenyi Biotec). Average 
purity of TB10.44-11-tetramer positive, CD8+ T cells was 85%, with 1.4% 
contaminating CD4+ T cells. The tetramer negative population was subsequently 
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washed and then enriched for polyclonal CD8+ T cells via Mouse CD8+ T cell 
isolation kit (Miltenyi Biotec). Average purity of polyclonal, non-TB10.44-11-tetramer 
positive, CD8+ T cells was 75% with 0.8% contaminating CD4+ T cells and 13% 
contaminating TB10.44-11-tetramer positive CD8+ T cells. The T cells were counted 
using a hemocytometer and resuspended in supplemented complete RPMI 1640 
media before being used in experiments.  
 
Listeria infections 
The recombinant Listeria strains have been previously described [231]. For 
in vitro infections, they were grown to an OD600 of 0.6-1.0 in BHI media (Sigma 
Aldrich) with 10 μg/ml chloramphenicol (Sigma Aldrich) at 30°C. Macrophages 
were infected with the Listeria strains using a MOI 50, for 45 minutes. Extracellular 
bacteria were eliminated by adding 60 μg/ml gentamicin (Sigma Aldrich) for 20 
minutes. Bacterial burden was assessed by lysing the infected macrophages with 
1% TritonX-100 in PBS and plating serial dilutions of the lysate on BHI agarose 
supplemented with 10ug/ml chloramphenicol (Sigma Aldrich, St. Louis, MO). 
Recombinant listeriolysin (Prospec, East Brunswick, NJ) was added in some 
experiments at 2 μg/ml for 30 minutes, and any excess was washed away. 
Bafilomycin (InvivoGen, San Diego, CA) was added in some experiments at 5 μM 
for 30 minutes, before being washed away.  
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Generation of TB10.4-overexpressing Mtb strains  
pJR1103 was cleaved with EcoRI-HF and SalI-HF [290]. mCherry preceded 
by the groEL2 promoter from H37Rv was inserted by HiFi Assembly. The resulting 
plasmid was cleaved with NdeI and NotI-HF. The esxGH gene from H37Rv, along 
with 12 upstream nucleotides, was inserted by HiFi Assembly following the 
plasmid-borne tetracycline-inducible promoter. All enzymes used above were 
purchased from New England Biolabs. The resulting plasmid (pGB6) was 
electroporated into Mtb H37Rv and integrated at the L5 site. RNA was purified from 
induced and uninduced cultures using TRIzol (ThermoFisher) and chloroform 
extraction, followed by purification on Zymo columns. cDNA was produced with 
Superscript IV (ThermoFisher), and quantitative PCR was performed using the 
iTaq SYBR Green Supermix (Bio-Rad, Hercules, CA) on an Applied Biosystems 
Viia 7 thermocycler. 
 
Irradiated H37Rv  
The following reagent was obtained through BEI Resources, NIAID, NIH: 
Mycobacterium tuberculosis, Strain H37Rv, Gamma-Irradiated Whole Cells, NR-
14819. Briefly, H37Rv was grown to late-log phase, and γ-irradiation was carried 
out using 2.4 megaRads dose via 137Cs source. The irradiated H37Rv was gently 
sonicated using a cup-horn sonicator at a low power to disperse bacterial clumps 
while limiting bacterial lysis. The number of bacteria was approximated by 
measuring the turbidity at OD600 and correlating it with live H37Rv (OD600 = 1 is 
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equivalent to 3.0x108 CFU/ml). To pulse TGPMs, diluted, sonicated, γ-irradiated 
H37Rv were added to adherent macrophages for one hour before repeatedly 
washing the cultures to remove residual extracellular bacteria. Subsequently, 
TB10Rg3 or P25 T cells were added at a ratio of 1 T cell to 1 macrophages. After 
72 hours, the amount of IFNγ in the supernatants was measured using Mouse 
IFNγ ELISA MAX kits (Biolegend, San Diego, CA). 
 
Flow Cytometry Analysis 
The following cell surface antigens were detected by flow cytometry using 
the following antibodies: mouse CD4 (clone GK1.5), CD8 (clone 53-6.7), CD3ε 
(clone 145-2C11), CD69 (clone H1.2F3), I-A/I-E (clone M5/114.15.2), and H-2Kb 
(clone AF6-88.5) (all from Biolegend). BV421- and APC-conjugated, TB10.44-11-
loaded, H-2Kb tetramers were obtained from the National Institutes of Health 
Tetramer Core Facility (Emory University Vaccine Center, Atlanta, GA). Zombie 
Violet Fixable viability dye (Biolegend) or the Live/Dead Fixable Far Red Dead Cell 
stain (ThermoFisher) were used for distinguishing live from dead cells. To stain for 
the Nur77 transcription factor, the Nur77 monoclonal antibody (clone 12.14) was 
used in combination with the Foxp3 Transcription Factor Staining Buffer Set (both 
from ThermoFisher) by the manufacturer’s protocol. Live/dead viability staining 
and surface staining were done for 20 minutes at 4°C, and intracellular staining 
was done for 30 minutes at room temperature. Samples were then fixed with 1% 
paraformaldehyde/PBS for 1 hour before being analyzed by a MACSQuant flow 
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cytometer (Miltenyi Biotec). FlowJo Software (Tree Star, Portland, OR) was used 
to analyze the collected data. Single lymphocytes were gated by forward scatter 
versus height and side scatter for size and granularity, and dead cells were 
excluded. 
  
Normalization and statistical analysis 
 To compare the cellular expression of Nur77 and CD69 expression levels 
between time points, the MFI values were normalized as follows: experimental 
values were divided by the difference between the isotype control MFI (minimum 
response) and the peptide control MFI (maximum response).  
Each Figure represents a minimum of 2 similar experiments, with 2 to 4 
biological replicates in each experiment. Data are represented as mean ± standard 
error of the mean (SEM). For comparing two groups, a two-tailed, unpaired 
student’s t-test was used. For more than two groups, the data were analyzed using 
a one-way ANOVA. A p value < 0.05 was considered to be statistically significant. 
Analysis was performed using GraphPad Prism, Ver. 7 (GraphPad Software, La 
Jolla, CA). 
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